ANNUAL REPORT

2025-2026

BCIL

Biotech Consortium India Limited

BIOTECH CONSORTIUM INDIA LIMITED

36th
ANNUAL REPORT
2025 - 2026

BOARD OF DIRECTORS

Dr. Shekhar C. Mande (Chairman)
President, INSA, Former Director General, Council of Scientific and Industrial Research (DG, CSIR) and Former Secretary, Department of Scientific and Industrial Research, Ministry of Science and Technology (Secy-DSIR), Govt. of India

Shri Shashank Dixit
Chief General Manager, IDBI Bank Limited, New Delhi (Nominee of IDBI Bank Limited)

Ms. Smita Kumar
Retired Director General, Postal Services, (Nominee of Specified Undertaking of Unit Trust of India -SUUTI)

Dr. Sanghamitra Pati
Additional Director General, Indian Council of Medical Research (ICMR), New Delhi & Director & Scientist-G, ICMR-Regional Medical Research Centre, Bhubaneswar (Nominee of ICMR)

Shri Praveen Roy
Scientist 'G' and Head (TTI), Department of Science & Technology (DST), New Delhi, Ministry of Science & Technology, Govt. of India (Nominee of DST)

Dr. Devendra Kumar Yadava
Deputy Director General (Crop Science), Indian Council of Agricultural Research (ICAR), New Delhi (Nominee of ICAR).

Dr. Ram A. Vishwakarma
Former Director, CSIR-Indian Institute of Integrative Medicine (CSIR-IIIM), Jammu.

Dr. Purnima Sharma
Managing Director, Biotech Consortium India Limited

AGM (FINANCE) & COMPANY SECRETARY
Shri Mukesh Gupta

MANAGER (S)
Smt. Anita Sharma
Shri Manoj Gupta
Shri Manish Sharma
Shri Vinod Kumar

DEPUTY MANAGER(S)
Smt. Sherly Charles
Shri Krishan Singh Rawat

STATUTORY AUDITORS
M/s Aggarwal Vineeta & Co.

BANKERS
Canara Bank
HDFC Bank Limited
IDBI Bank Limited
ICICI Bank Limited

REGISTERED OFFICE
5th Floor, Anuvrart Bhawan,
210, Deen Dayl Upadhyaya Marg,
New Delhi-110002
Website: www.biotech.co.in
Email: info.bcil@biotech.co.in

NOTICE

Notice is hereby given that the Thirty Sixth Annual General Meeting of the Members of Biotech Consortium India Ltd. will be held on Tuesday, 8th September 2026 at 11.30 a.m. through Video Conferencing/Other Audio-Visual Means ("VC/OAVM") to transact the following businesses:

ORDINARY BUSINESSES

1. **Adoption of Financial Statements**

   To receive, consider and adopt the audited Financial Statements of the company for the financial year ended March 31, 2026, together with the reports of the Board of Directors and the Auditors thereon.

2. **Appointment of Director**

   To appoint a Director in place of Dr. Shekhar C Mande (DIN-10083454) who retires by rotation and being eligible, offers himself for reappointment.

3. **Appointment of Director**

   To appoint a Director in place of Dr. Ram Vishwakarma (DIN-07108315), who retires by rotation and being eligible, offers himself for reappointment.

SPECIAL BUSINESSES

4. **Appointment of Dr. Devendra Kumar Yadava (DIN-11695257) as Director of the company**

   To consider and if thought fit, to pass with or without modification (s), the following resolution as an **Ordinary Resolution**:

   "RESOLVED THAT Dr. Devendra Kumar Yadava (DIN-11695257), Deputy Director General, Indian Council of Agricultural Research (ICAR), New Delhi who was appointed as a Nominee Director of ICAR on May 04, 2026 be and is hereby appointed as Nominee Director of ICAR".

5. **Appointment of Shri Praveen Roy (DIN-11696297) as Director of the company**

   To consider and if thought fit, to pass with or without modification (s), the following resolution as an **Ordinary Resolution:**

   "RESOLVED THAT Shri Praveen Roy (DIN-11696297), Scientist-G and Head (TTI), Department of Science & Technology (DST), New Delhi who was appointed as a Nominee Director of the DST on May 04, 2026 be and is hereby appointed as Nominee Director of DST".

6. **Approval of remuneration of Dr. Purnima Sharma as Managing Director of the company as per Section II of Part II of the Schedule V of the Companies Act, 2013**

   To consider and if thought fit, to pass with or without modification (s), the following resolution as a **Special Resolution**:

   "RESOLVED THAT pursuant to the provisions of section 197 read with schedule V of the Companies Act, 2013 and other applicable provisions, if any, of the Companies Act, 2013 (including any statutory modification or re-enactment thereof for the time being in force) and pursuant to Articles of Association of the company, the Members of the company hereby approves that the remuneration approved by the Board in its 135th meeting held on December 28, 2022 be paid as minimum remuneration to Dr. Purnima Sharma irrespective of the fact whether company profits are inadequate in any financial years between April 01, 2026 to May 22, 2028.

NOTES:

1. An Explanatory Statement pursuant to Section 102 of the Companies Act, 2013 relating to the Special Businesses to be transacted at the Annual General Meeting (AGM) is annexed hereto and forms part of this notice.

2. In view of General Circular No, 09/2025 dated September 19, 2025, issued by the Ministry of Corporate Affairs ("MCA Circular") and in compliance with the provisions of the Companies Act, the 36th AGM of the company is being conducted through VC/OAVM Facility on Tuesday, 8th September, 2026 at 11.30 a.m. which does not require physical presence of Members at a common venue. The deemed venue for the 36th AGM shall be the Registered Office of the company.

3. Attendance of the Members participating in the 36th AGM through VC/OAVM Facility shall be counted for the purpose of reckoning the quorum under Section 103 of the Act.

4. In terms of the MCA Circulars, since the physical attendance of Members have been dispensed with, there is no requirement of appointment of proxies. Accordingly, the facility of appointment of proxies by Members under Section 105 of the Act will not be available for the 36th AGM. However, in pursuance of Section 112 and Section 113 of the Act, representatives of the Members may be appointed for the purpose of participation in the 36th AGM through VC/OAVM Facility.

5. Institutional/Corporate shareholders (i.e. other than individuals/HUF, NRI, etc.) are encouraged to attend and vote at the 36th AGM through VC/OAVM facility. They will be required to send a scanned copy (pdf/jpg format) of their board or governing body's resolution/authorization etc., authorizing their representative to attend and vote in the AGM on their behalf. The said resolution/ authorization shall be sent to by email through their registered email address to mukesh@biotech.co.in with a copy marked to **manish@biotech.co.in.**

6. Members may note that this Notice and the Annual Report for the year 2025-26 will also be available on the company website viz **www.biotech.co.in.**

7. Since the AGM will be held through VC/ OAVM Facility, Proxy Form, Attendance Slip and Route Map of AGM is not annexed in this Notice.

8. Instructions for Members for participating in the 36th AGM through VC/OAVM are as under:

a. Members may join the 36th AGM through VC/OAVM Facility which shall be kept open for the Members from 11.00 a.m. IST i.e. 30 minutes before the time scheduled to start the 36th AGM and the company may close the window for joining the VC/OAVM Facility 30 minutes after the scheduled time to start the 36th AGM.

b. Members will be able to attend the 36th AGM through VC/OAVM Facility through the weblink which is available at our website i.e. www.biotech.co.in.

c. On clicking the link, the Members will be able to attend and participate in the proceedings of the AGM.

d. Members who need technical assistance before or during the thirty sixth AGM can contact at info.bcil@biotech.co.in or helpline nos. –9350228448 or 9818636186.

9. Pursuant to Section 101 and Section 136 of the Companies Act, 2013 read with relevant Rules made thereunder, companies can serve Annual Reports and other communications through electronic mode to those Members who have registered their e-mail address either with the company or with the Depository. Members who have not registered their e-mail address with the company can now register the same by submitting a request to the company. Members holding shares in demat form are requested to register their e-mail address with their Depository Participant(s) only. Members of the company, who have registered their e-mail address, are entitled to receive such communication in physical form upon request.

10. Members are requested to intimate changes, if any, pertaining to their name, postal address, e-mail address, telephone/mobile numbers, PAN, registering of nomination, power of attorney registration, Bank Mandate details, etc. to their DPs in case the shares are held in electronic form and to the Company at **mukesh@biotech.co.in** in case the shares are held in physical form, quoting their folio number.

11. The Register of Directors and Key Managerial Personnel and their shareholding maintained under Section 170 of the Companies Act, 2013, the Register of contracts or arrangements in which the Directors are interested under Section 189 of the Companies Act, 2013 will be available for inspection electronically during the AGM.

By Order of the Board of Directors

(Mukesh Gupta)

AGM (Finance) & Company Secretary

Date : 13.07.2026

Place : New Delhi

Registered Office:

5th Floor, Anuvrat Bhawan,

210, Deendayal Upadhyaya Marg,

New Delhi – 110 002

CIN: U73100DL1990PLC041486

Annexure to Notice

EXPLANATORY STATEMENT SETTING OUT MATERIAL FACTS AS REQUIRED UNDER SECTION 102 OF THE COMPANIES ACT, 2013 IN RESPECT OF ITEMS OF SPECIAL BUSINESS AS PER THE NOTICE

ITEM No. 4

Dr. Devendra Kumar Yadava (DIN-11695257), Deputy Director General, Indian Council of Agricultural Research (ICAR), New Delhi was appointed as Nominee Director of ICAR with effect from May 04, 2026 on the Board of the company in accordance with the Articles of Association of the company. It is proposed to regularize the appointment of Dr. Devendra Kumar Yadava in the ensuing Annual General Meeting.

Your Directors recommend the resolution for approval of the Members.

None of the Directors or Key Managerial Personnel of the company and their relatives, other than Dr. Devendra Kumar Yadava for his respective appointment, is concerned or interested, financially or otherwise, in the Resolution. The Board recommends the Ordinary Resolution as set out at item no. 4 for approval of the Members.

ITEM No. 5

Shri Praveen Roy (DIN-11696297), Scientist-G and Head (TTI), Department of Science & Technology (DST), New Delhi was appointed as Nominee Director of the DST with effect from May 04, 2026 on the Board of the company in accordance with the Articles of Association of the company. It is proposed to regularize the appointment of Shri Praveen Roy in the ensuing Annual General Meeting.

Your Directors recommend the resolution for approval of the Members.

None of the Directors or Key Managerial Personnel of the company and their relatives, other than Shri Praveen Roy for his respective appointment, is concerned or interested, financially or otherwise, in the Resolution. The Board recommends the Ordinary Resolution as set out at item no. 5 for approval of the Members.

ITEM No. 6

The Board of Directors in its 134th meeting held on September 28, 2022 had renewed the appointment Dr. Purnima Sharma as Managing Director of the company for another period of five years with effect from May 23, 2023 considering the sincere and dedicated efforts put in by Dr. Purnima Sharma in managing the affairs of the company. Even during the last 2 years of COVID pandemic, operations of BCIL have sustained themselves due to dynamic leadership of Dr. Purnima Sharma. The Board also noted that Dr. Sharma is always keen to diversify into newer areas of activities. The Board in its 135th meeting held on December 28, 2022 had approved terms and conditions of reappointment of Dr. Purnima Sharma as Managing Director of the company. The Board also approved that the remuneration approved by the Board be paid as minimum remuneration to Dr. Purnima Sharma irrespective of the fact whether company profits are inadequate in any financial years between April 01, 2023 to March 31, 2026. The same was approved by the Members of the company in the Thirty Third Annual General Meeting held on September 01, 2023.

The Board in its 150th meeting held on July 13, 2026 had considered that remuneration of Dr. Purnima Sharma, Managing Director of the company may exceed 5% of the net profits of the company during her tenure as Managing Director of the company. However, it will be well within limit of Rs. 84.00 lakhs as specified in Section

II of Part II of the Schedule V of the Act. It is proposed that the remuneration approved by the Board in its 135th meeting held on December 28, 2022 be paid as minimum remuneration to Dr. Purnima Sharma irrespective of the fact whether company profits are inadequate in any financial years between April 01, 2026 to May 22, 2028.

As per the provisions of Sections 196 and 197 read with Schedule V of the Companies Act, 2013, the remuneration of the Managing Director should be approved by Board of Directors and Members of the company. The Board of Directors has approved and recommended remuneration package as per Section II of Part II of the Schedule V of the Companies Act, 2013 for the period 01/04/2026 to 22/05/2028 to the Members for approval.

Your Directors recommend the resolution for approval of the Members including the terms and conditions as set out in the resolution.

None of the Directors or Key Managerial Personnel of the company and their relatives, other than Dr. Purnima Sharma is concerned or interested, financially or otherwise, in the Resolution. The Board recommend the Special Resolution as set out at item no. 6 for approval of the Members.

The details of remuneration of Dr. Purnima Sharma as Managing Director of the Company approved by the Board in its 135th meeting held on December 28, 2022 are set out as below:

Basic Pay and Pay Scale:

A starting basic pay of Rs. 220300* in the pay scale 135700-4700-182700-4700-253200.

* with effect from 23rd May 2023

Dearness Allowance:

Linked to the all-India Consumer Price Index and as followed by the all-India financial institutions.

House Rent Allowance:

As per rules of the company. HRA will be payable at the rate of 30% of the basic pay. Alternately, leased accommodation may be provided by the company, the rent of which shall not exceed 50% of the basic pay.

Perquisites:

a. **Ordinary Leave:**

   As per rules of the company

b. **Other Leave:**

   As per rules of the company

c. **Leave Encashment:**

   As per rules of the company

d. **Contributory Provident Fund:**

   As per rules of the company

e. **Travelling Allowance:**

   As applicable to Directors of the company

f. **Gratuity:**

   As per rules of the company

g. **Medical Reimbursement and Medical Allowance:**

   For self and family, subject to a ceiling of half month's basic pay in a year as per rules of the company.

h. **Medical Insurance:**

   As per rules of the company

i. **Personal Accident Insurance:**

   Premium not exceeding Rs.1,500 per annum

j. **Telephone and Internet:**

   Free telephone and internet at residence at the expense of the company.

k. Car:

Free use of company's car for official purposes. Use of car for private purposes will be permitted on payment as per rules applicable to Chief Executive of the Company and as decided by the Board from time to time i.e presently Rs. 250 per 500 km and proportionately thereafter.

l. Club Membership:

Membership fee of one club.

m. Leave Fare Concession:

To and fro air fare for self and family to hometown/any place once in a year. For traveling outside India, reimbursement will be restricted upto regular fare of a distance of 2100 km from Delhi (in India) of Air India or actual expenses incurred, whichever is lower.

n. Entertainment Allowance:

Not exceeding one month's pay plus DA in a year for official entertainment.

o. Termination of service:

On three months' notice from either side

With regard to all matters not specifically mentioned above, the terms and conditions of service shall be the same as those applicable to senior executives of the company from time to time. The terms and conditions may be altered as and when deemed necessary".

The requisite information specified in Section II of Part II of the Schedule V is given below for kind perusal of the Members:

I. GENERAL INFORMATION

1. Nature of Industry

Consultancy in biotechnology

2. Date or expected date of commencement of commercial production

Existing company in operation since 1991

3. In case of new companies, expected date of commencement of activities as per project approved by the financial institute appearing in the prospectus

Not Applicable

4. Financial performance based on given indicators

Rs. in lakhs

Sl. No.	Particulars	2025-26	2024-25	2023-24
1.	Income	612.43	611.92	573.60
2.	Net Profit/ (Loss)	12.70	5.10	4.11
3.	Paid-up share capital	537.00	537.00	537.00
4.	Reserves & Surplus	2445.94	2433.25	2428.99

5. Foreign investments or collaborators, if any

Nil

II. INFORMATION ABOUT THE APPOINTEE

1. Background details including recognition or awards

Dr. Purnima Sharma is a doctorate in Microbiology from Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, the prestigious autonomous institution and deemed Medical University of national importance under the Ministry of Health, Government of India with Post Doctoral experience from IIT, Mumbai, and has to her credit many awards for excellence in academics. She is also a Registered Technology

Transfer Professional (RTTP) which gives her the credibility in over 60 countries around the world as an expert in Technology Transfer, Knowledge Transfer or Knowledge Exchange. She is also a Fellow of the Society for Technology Management (STEM), a recognition given for her sustained and significant contribution in the realm of Intellectual property management and knowledge transfer.

She has vast experience in the area of IP management, technology transfer, project management and in coordinating diverse range of biotech projects of national and international relevance such as status studies, market analysis reports, feasibility studies etc. She has also coordinated the preparation of business plans for setting up biotechnology incubators and parks in different States. She is also a member of the National Academy of Sciences, the oldest academy of sciences in India. She is/has been also a member of national and state level committees responsible for biotech development and commercialization including:

- Steering cum Project Monitoring Committee under the National Biotechnology Park Scheme of Department of Biotechnology, GoI, New Delhi.
- Research Advisory Committee for Biotechnology and Life sciences of Shriram Institute of Industrial Research, Delhi
- Expert Review Committee for 'National Centre for Quantum Accelerator Chip using Lithium' of Ministry of Electronics and Information Technology (MeitY), New Delhi
- Project Review & Steering Group of Ministry of Electronics and Information Technology (MeitY), New Delhi
- Working Group on Photonics under EMCD (R&D in Electronics Division) of Ministry of Electronics and Information Technology (MeitY), New Delhi
- Working Group on Additive Manufacturing of Ministry of Electronics and Information Technology (MeitY)
- Technology Transfer Committee of Gujarat Biotechnology Research Centre (GBRC), Gandhinagar
- CII National Committee on Biotechnology
- National Academy of Science, India (NASI)
- She is also a Guest Faculty under Faculty of Agriculture and NEATE Hub of Assam Agricultural University

2. Past remuneration

Financial Years	Remuneration (Rs. in lakhs) *
2023-24	40.86
2024-25	44.75
2025-26	42.43

* Excluding retiral benefits.

3. Job profile and her suitability

Dr. Purnima Sharma serves as Managing Director of the company. She is in the overall control and management of the company. She is also the mentor behind all the policies of the company. She takes decisions in all strategic matters under supervision and guidance of the Board. To sustain the growth path, it is essential for the company to adequately remunerate her as per market norms. Accordingly, it is proposed to approve the existing remuneration package of Dr. Purnima Sharma.

4. Remuneration proposed

The detailed remuneration has been explained hereinabove in the resolution of the notice calling the Annual General Meeting of the company.

5. Comparative remuneration profile with respect to industry, size of the company, profile of the position and person

The remuneration package of Dr. Purnima Sharma is far below that drawn by the peers in the similar capacity in established companies engaged in consultancy e.g. Ernst &Young, McKinsey & Company, PWC etc.

6. Pecuniary relationship directly or indirectly with the company, or relationship with the managerial personnel, if any

Apart from having the transactions as disclosed in Annual Report for the financial year ended March 31, 2026 pursuant to the provision of "Accounting Standard 18 (AS 18) and holding 10 equity shares of the company, there was no other pecuniary relationship directly or indirectly with the company or relationship with managerial personnel.

III. OTHER INFORMATION

1. Reason of loss or inadequate profits

Since the appointment of Dr. Purnima Sharma on the Board, financial performance and visibility of the company has increased significantly which is evident from the fact that reserves of the company have increased from Rs. 211.19 lakhs in the year 2005-06 to Rs. 2445.94 lakhs in the year 2025-26.

The remuneration is exceeding 5% of net profits of the company because the company is engaged in providing consultancy services in a specialized area of biotechnology and therefore, income and profitability are low and not expected to match with those observed in case of manufacturing companies.

2. Steps taken or proposed to be taken for improvement

The company is consistently expanding the scope of existing activities and is also proactively diversifying into new activities for which the skills and knowledge base is being strengthened.

3. Expected increase in productivity and profits in measurable terms

The above measures are expected to enhance the visibility of the company as a specialized consultancy agency in the area of biotechnology and also increase the profitability over the years at least by 3-7%.

IV. DISCLOSURES

1. **Remuneration package of the managerial person**

   Fully described in the Item No. 6 and the respective explanatory statement as stated above

By Order of the Board of Directors

(Mukesh Gupta)

AGM (Finance) & Company Secretary

Date : 13.07.2026

Place : New Delhi

Registered Office:

5th Floor, Anuvrat Bhawan,

210, Deendayal Upadhyaya Marg,

New Delhi – 110 002

CIN: U73100DL1990PLC041486

DIRECTORS REPORT

To the Members,

Your Directors have pleasure in presenting the Thirty Sixth Annual Report of the company along with the audited statement of accounts for the year ended 31st March 2026:

FINANCIAL RESULTS

(Rs. in lakhs)

Particulars	2025-2026	2024-2025
Income from Operating Activities	414.33	418.08
Income from Non-Operating Activities	198.10	193.84
GROSS INCOME	**612.43**	**611.92**
Administrative & Other Expenses	598.22	606.53
Profit before Depreciation & Taxes	**14.21**	**05.39**
Add/(Less)		
Exceptional and Extra Ordinary Income	10.75	06.11
Depreciation	(00.24)	(00.56)
Taxes	(12.02)	(05.84)
Net Profit/ (Loss)	**12.70**	**05.10**
Surplus brought forward from previous year	2430.40	2425.30
Surplus carried to Balance Sheet	**2443.10**	**2430.40**

During the year under review, your company sustained its operations and achieved a net profit of Rs. 12.70 lakhs.

It is decided not to transfer any amount to the Reserves for the financial year under review. No dividend is proposed for the year. The closing balance of the retained earnings of the company for FY 2026 after all appropriation and adjustments was Rs. 2443.10 lakhs.

OPERATIONS

Your company contributed towards strengthening the national innovation ecosystem by providing a range of business support services covering Intellectual Property (IP) Management, Transfer of Technologies, R&D Collaborations, Consultancy, Project Management, Regulatory Support and Information Dissemination.

INTELLECTUAL PROPERTY MANAGEMENT AND TECHNOLOGY TRANSFER SERVICES

During the year under review, your company continued its efforts towards innovation management through a range of services including capacity building, intellectual property protection, facilitating R&D collaborations and transfer of technologies. As part of these initiatives, your company successfully organized 12 awareness-cum-capacity building programmes on Intellectual Property Rights (IPR) management in addition to conducting more than 8 awareness and outreach programmes on technology transfer at various DBT autonomous Institutions, Indian Institutes of Science Education and Research (IISERs) and National Institutes of Pharmaceutical Education and Research (NIPERs). These programmes sensitized over 500 scientists, innovators and students on various aspects of intellectual property protection, technology transfer and commercialization.

Your company continued to play a pivotal role in strengthening the intellectual property portfolios of innovators at Research Institutions and Universities by providing end-to-end intellectual property management and strategic advisory services. During the year, your company conducted 28 prior art and novelty assessment studies; drafted, filed and facilitated prosecution of 46 Indian patent applications and 10 Patent Cooperation Treaty (PCT) applications/national phase filings and completed 5 Freedom-to-Operate (FTO) studies. Through comprehensive IP assessment and advisory, your company enabled innovators and institutions to secure robust intellectual property protection in appropriate jurisdictions thereby enhancing the commercial potential and global competitiveness of their IPs.

Your company also played a proactive role in bridging the gap between academia and industry by engaging with research institutions, universities and industry to scout for technologies, screening the ones with commercial potential following a comprehensive evaluation and facilitating their transfer to Industry for societal and economic benefit. During the year, your company carried out technology assessment and evaluation of 68 technologies to identify promising leads followed by identifying suitable industry partners for technology transfer and/or R& D collaboration. Your company facilitated detailed negotiations between technology developers and industry by extending comprehensive transaction support through execution of 7 Non-Disclosure Agreements (NDAs) and 3 Material Transfer Agreements (MTAs). As a result of these efforts, your company successfully facilitated 5 industry–academia R&D collaborations and transferred the following 3 technologies to industry in addition to providing strategic advisory to researchers on intellectual property ownership, commercialization pathways and partnership structures for translation of research into market-ready technologies.

a. A tick controlling formulation of dimethicone
b. Process for the development of Bio-polymer based edible coating materials from agricultural and food processing by-products.
c. Green compounding technology for production of antibacterial polymer nanocomposites

To expand access to innovative IPs, your company executed Memoranda of Agreements (MoAs) with Indian Institutes of Science Education and Research (IISERs) to assist them in IP management, technology transfer, capacity building and promotion of research-based startups and spin-off enterprises. These MoAs were executed in the presence of Shri Dharmendra Pradhan, Hon'ble Minister of Education, Government of India; the Secretary, Department of Higher Education, Ministry of Education; the Secretary, Department of Science & Technology; and Dr. Shekhar C. Mande, Chairman, BCIL, President, INSA, former Secretary, DSIR and Director General, CSIR thereby strengthening your company's position as a trusted partner for research translation and innovation management. During the year, National Institute of Pharmaceutical Education and Research (NIPER), Ahmedabad also partnered with your company to collaborate in these strategic areas, reflecting the growing confidence of leading academic institutions in your company's expertise.

In addition, your company also proactively engaged with State Governments, State Science & Technology Councils, universities and research institutions to strengthen innovation and entrepreneurship ecosystems across the country. During the year, the Gujarat State Biotechnology Mission (GSBTM), Government of Gujarat and Gujarat Biotechnology University (GBU) entered into Memoranda of Agreements (MoAs) with your company to leverage its expertise in innovation management, technology transfer, industry engagement and capacity building. These strategic collaborations will facilitate further development and transfer of technologies, strengthening startup ecosystem and industry–academia partnerships

PROJECT MANAGEMENT

Your company continued the management of HRD programmes of DBT.

During the year, your company continued to manage the DBT - Conference, Travel, Exhibition, Popular Lectures (CTEP) programme of DBT for which your company is the Management Cell.

Your company was also selected through an open tender process conducted by Regional Centre for Biotechnology (BRIC-RCB), Faridabad for assisting them in conducting a computer-based exam for selection of candidates for ten posts of "Scientist C" in Department of Biotechnology (DBT) from among 4000 applicants.

On behalf of the U.S. Department of State's Cooperative Threat Reduction Office, Sandia National Laboratories' Global Chemical and Biological Security group has approached your Company to collaborate with them for conducting a workshop on "Strengthening oversight of Dual-Use Research of Concern (DURC) and Know-Your-Customer/Collaborator (KYC) due-diligence." The project is expected to commence early next year.

PROJECT CONSULTANCY

Your company was engaged by the United National Development Programme (UNDP) to provide support to the Working Group on 'Business and Biodiversity Conservation' set up by the National Biodiversity Authority (NBA) for the purpose of contributing to the operationalization of Targets 15&19 of the Kunming-Montreal Global Biodiversity Framework (KMGBF).

During the year, your company was also engaged by UNDP for conducting Regional/Thematic Workshops for preparation and submission of the Seventh National Report (NR7) to the Convention on Biological Diversity (CBD).

Your Company was also entrusted with the assignment of preparing a Detailed Project Report (DPR) for the establishment of a Technology Transfer Office (TTO) at the National Centre for Additive Manufacturing (NCAM), Hyderabad a company established by the Ministry of Electronics and Information Technology (MeitY), Government of India.

The proposed TTO is aimed at facilitating the protection, management and commercialization of innovations and technologies developed in the field of Additive Manufacturing (AM), particularly those supported by MeitY.

The DPR envisages the creation of a structured framework for technology transfer, industry engagement and promotion of innovation-led entrepreneurship in the additive manufacturing ecosystem.

REGULATORY SUPPORT SERVICES

Biosafety and Biosecurity Support Services

Your company continued to support public sector research institutions for compliance with biosafety regulations as a partner in the "All India Network Project on Biotech Crops" of Indian Council of Agricultural Research (ICAR). Your company is providing guidance to more than 10 genetically engineered and gene edited plants under development in key ICAR research Institutions.

Your company is also facilitating other research institutions and universities in the country in facilitating approvals from regulatory authorities for conduct of confined field trials and biosafety evaluation. Research Institutions included National Agri-Food Biotechnology Institute (NABI), Mohali for GE banana fortified with Pro-Vitamin A (PVA) and Iron; ICAR-Central Potato Research Institute (CPRI), Shimla for late blight resistant GM potato; Assam Agricultural University (AAU), Jorhat for insect resistant chickpea; ICAR-National Institute of Plant Biotechnology (NIPB), New Delhi for insect resistant pigeonpea and University of Delhi for herbicide tolerant mustard. Your company also provided biosafety support services to private company regarding regulatory testing of pink bollworm resistant cotton technology.

Your company organized workshops on new developments in agri biotechnology with a focus on genetic engineering and gene editing at state level in association with state agricultural universities and with support from Federation of Seed Industry Association (FSII). During the year, workshops were organized at Lucknow, Ludhiana and Hyderabad. Your company continued to provide regulatory support services for approval of importation and marketability of genetically modified yeast (GM yeast) and its use by grain-stock based distilleries.

Your company prepared a report on comparative analysis of regulatory documents of four countries viz. Bangladesh, India, Philippines and Mongolia as part of a multi-country project being coordinated by Korea Institute for Promoting Biosafety Cooperation (KIPABiC).

Your company continued to work for harmonization of GM food safety guidance in the region and facilitated capacity building workshops in India and Sri Lanka working in close coordination with FSSAI and Ministry of Health, Government of Sri Lanka. These activities were undertaken in association with Agriculture and Food System Institute, Washington, DC and provided technical support for activities in Bangladesh and India. Your company continued to produce technical documents and newsletters under the South Asia Biosafety Program (SABP).

INFORMATION SERVICES

Your company continued to provide value added information services to the stakeholders. The members of Biotechnology Club of your company consisting of industry, research institutions, universities and individuals were kept abreast with the latest developments in biotechnology through regular information updates and newsletters.

FUTURE STRATEGY

The Government of India has fundamentally reoriented its science, technology and innovation ecosystem towards research translation, innovation management, technology transfer and commercialization through landmark initiatives such as the Anusandhan National Research Foundation (ANRF), the BioE3 Policy, the National Education Policy (NEP 2020), the National IPR Policy, Startup India, the Atal Innovation Mission etc. A common thread across these initiatives is the recognition that creating economic and societal value from publicly funded research requires professionally managed systems for intellectual property (IP) management, technology assessment, industry engagement, licensing, collaborative research, startup facilitation etc. Your company possesses over three decades of proven expertise in these domains and has successfully transferred more than 85 technologies; facilitated industry–academia collaborations; managed IP portfolios; undertaken technology assessment and valuation; negotiated and structured licensing, collaborative R&D and confidentiality agreements with clear provisions relating to IP ownership, inventorship, access rights and commercialization; provided regulatory support; and has developed a strong network spanning research institutions, universities, industry, startups and Government agencies. These capabilities represent a unique asset that closely aligns with the objectives of the Government's emerging innovation-led growth agenda. To leverage these national opportunities, your company is strategically positioning itself as a preferred innovation management and technology transfer partner through proactive initiatives to expand access to innovative IPs by executing agreements with State S&T Councils, leading Central and State Universities, Research Institutes as well as through formal arrangements with organizations with complementary strengths including downstream translation of research into market-ready products aimed at integrating all stakeholders i.e., technology providers, industry, startups, investors, incubators, regulatory experts, testing and validation facilities and funding agencies.

This strategic repositioning would reinforce your company's role as a key organization supporting India's transition towards an innovation-driven economy, while creating sustainable and diversified revenue streams through institutional retainerships, innovation management services, technology transfer fees, advisory and consulting services, capacity-building programmes, project management and long-term strategic partnerships. Your company will continue to enhance the skill base of existing personnel and also engage suitable professionals in line with the company's future strategy.

RESOURCES

Your company's finances were based on income generated from its existing resources and operations. There was no increase in the share capital and no funds were borrowed during the year. As desired by the institutional shareholders, most of the shares have been dematerialized through M/s Skyline Services Pvt. Ltd., New Delhi as registrars. The shares are held in electronic form with the National Securities Depository Limited (NSDL).

AUDITORS' REPORT

Observations of the Auditors read together with relevant notes to accounts are self-explanatory and therefore no further clarification is required.

During the year under review, the Statutory Auditors of the company have not reported any fraud committed by its officers or employees as specified under Section 143(12) of the Act to the Financial Advisory Committee.

AUDITORS

M/s Aggarwal Vineeta & Co., Chartered Accountants were appointed as Auditors of the company for a term of 3 (three) year at the AGM held on September 15, 2025. The Auditors have confirmed that they are not disqualified from continuing as Auditors of the company.

PERSONNEL

Employees were deputed for training programmes, seminars and workshops to enhance their exposure, expertise and participation skills. No employee received remuneration exceeding the limits prescribed under Rule 5(2) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules 2014.

CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION

Your company is a service organization and is not engaged in any direct manufacturing activity. Therefore, conservation of energy and technology absorption are not under the purview of its activities.

FOREIGN EXCHANGE EARNINGS AND OUTGO

Your company earned Rs. 13.51 lakhs in foreign currency towards consultancy fee and spent Rs. 12.52 lakhs in foreign currency.

INTERNAL FINANCIAL CONTROLS

The company has in place well defined and adequate internal controls commensurate with the size of the company and the same were operating effectively throughout the year.

RISK MANAGEMENT

The Board of Directors of the company has framed, implemented and monitored the risk management plan for the company. The Board is responsible for monitoring and reviewing the risk management plan and ensuring its effectiveness. The Financial Advisory Committee has additional oversight in the area of financial risks and controls. The major risks identified by the businesses and functions are systematically addressed through mitigating actions on a continuing basis.

DIRECTORS

In accordance with the relevant provisions of the Articles of Association of the company and provisions of Companies Act, 2013, Dr. Shekhar C Mande (DIN-10083454) and Dr. Ram Vishwakarma (DIN-07108315), Directors retiring by rotation at the forthcoming Annual General Meeting and being eligible, offer themselves for reappointment.

During the year, the following Directors were inducted by the Board:

1. Dr. Devendra Kumar Yadava (DIN-11695257), Deputy Director General, Indian Council of Agricultural Research (ICAR), New Delhi as Nominee Director of the ICAR on May 04, 2026.
2. Shri Praveen Roy (DIN-11696297), Scientist-G and Head (TTI), Department of Science & Technology (DST), New Delhi as Nominee Director of the DST on May 04, 2026.

Towards this, requisite declaration under the relevant provisions of the Companies Act, 2013 has been received from the Directors. Further Dr. Anita Gupta, Dr. T R Sharma and Dr. Sanjeev Khosla ceased to be Director of the company after March 31, 2026.

The Board in its meeting July 13, 2026 approved and recommended the payment of remuneration to the Managing Director as per Schedule V of the Act for the period April 01, 2026 to May 22, 2028. The resolution for approval of remuneration of Dr. Purnima Sharma is placed in the agenda item for approval of the Members.

EXTRACT OF ANNUAL RETURN

As required under Section 134(3)(a) of the Act, the Annual Return for the FY 2024-25 is put up on the company's website and can be accessed at www.biotech.co.in. The Annual Return for the FY 2025-26 can be accessed at www.biotech.co.in, once it will be ready.

PARTICULARS OF CONTRACTS OR ARRANGEMENTS WITH RELATED PARTIES

All contracts / arrangements / transactions entered by the company during the financial year with related parties were in the ordinary course of business and on an arm's length basis. None of the transactions with any of related parties were in conflict with the company's interest.

The company's major related party transactions were with IDBI Bank Limited who has invested 27.93% in the capital of the company. The particulars of contracts or arrangements with related parties referred to in sub-section (1) of section 188 in the Form AOC-2 is given at Annex 1 and forms part of Directors' Report.

Your Directors draw attention of the Members to the Note 22.3b of the financial statement which sets out related party disclosures.

MAINTENANCE OF COST RECORDS

The company is not required to maintain cost records as specified by the Central Government under sub-section (1) of section 148 of the Companies Act, 2013 and accordingly such accounts and records are not made and maintained.

CORPORATE SOCIAL RESPONSIBILITY

The provisions of Section 135 of the Companies Act, 2013 read with the Companies (Corporate Social Responsibility Policy) Rules 2014 were not applicable to the company.

SUBSIDIARIES, JOINT VENTURES AND ASSOCIATE COMPANIES

During the year under review, no companies had become or ceased to be company's subsidiaries, joint ventures or associate companies.

DETAILS OF MATERIAL CHANGES FROM THE END OF THE FINANCIAL YEAR TILL THE DATE OF THIS REPORT

There is no material changes and commitments affecting the financial position of the company between the end of the financial year and date of this report.

SECRETARIAL STANDARDS

The company has followed applicable Secretarial Standards, i.e. SS-1 and SS-2, relating to 'Meetings of the Board of Directors' and 'General Meetings' respectively.

MEETINGS OF THE BOARD & ITS COMMITTTEES

Four meetings of the Board were held during the year on May 08, 2025, July 09, 2025, November 03, 2025 and January 29, 2026. Attendances of the Directors during these meetings are given below:

Name of the Director	Board Meeting No. and Date				No. of Board meeting held during tenure	No. of Board meeting attended	Attendance (%)
	145 08-05-25	146 09-07-25	147 03-11-25	148 29-01-26			
Dr. Shekhar C Mande	Yes	Yes	Yes	Yes	4	4	100%
Shri Shashank Dixit	Yes	No	Yes	Yes	4	3	75%
Dr. Anita Gupta	Yes	Yes	Yes	Yes	4	4	100%
Dr. Sanjeev Khosla	No	Yes	Yes	Yes	4	3	75%
Smt. Smita Kumar	Yes	Yes	Yes	No	4	3	75%
Dr. Sanghamitra Pati	No	Yes	Yes	No	4	2	50%
Dr. T R Sharma	Yes	Yes	Yes	Yes	4	4	100%
Dr. Ram A Vishwa-karma	Yes	Yes	Yes	Yes	4	4	100%
Dr. Purnima Sharma	Yes	Yes	Yes	Yes	4	4	100%

One meeting of the Financial Advisory Committee of the Board was held during the year on July 25, 2025. Attendances of the Directors during this meeting is given below:

Name of the Director	Meeting No. and Date	No. of meeting held during tenure	No. of meeting attended	Attendance (%)
	18 25-07-25			
Smt. Smita Kumar	Yes	1	1	100%
Shri Shashank Dixit	Yes	1	1	100%
Dr. Purnima Sharma	Yes	1	1	100%
Dr. Ram Vishwakarma	Yes	1	1	100%

PARTICULARS OF LOANS GIVEN, INVESTMENTS MADE, GUARANTEES GIVEN AND SECURITIES PROVIDED

As on March 2026, there is an investment of Rs. 0.19 lakhs in the equity shares of DLF Limited and outstanding vehicle loan of Rs. 0.88 lakhs given to a staff and the same is in compliance with Section 186 of the Companies Act, 2013.

VALUATION FOR ONE TIME SETTLEMENT

There was no instance of one time settlement with any bank or financial institution

PROCEEDINGS UNDER THE INSOLVENCY AND BANKRUPTCY CODE, 2016

No proceedings were initiated/pending against the company under the Insolvency and Bankruptcy Code, 2016.

GENERAL

Your Directors state that no disclosure or reporting is required in respect of the following items as there were no transactions on these items during the year under review:

1. Details relating to deposits covered under Chapter V of the Act.
2. Issue of equity shares with differential rights as to dividend, voting or otherwise.
3. Issue of shares (including sweat equity shares) to employees of the company under any scheme.
4. The Managing Director nor the Whole-time Directors of the company received any remuneration or commission from any of its subsidiaries.
5. No significant or material orders were passed by the Regulators or Courts or Tribunals which impact the going concern status and company's operations in future.

Your Directors further state that during the year under review, no cases were filed under the "Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013" (POSH Act). Internal Committee ("IC") has been constituted in accordance with the requirements of the POSH Act. The details of complaints received, disposed and pending during FY 2026 are as follows:

Particulars	No. of complaints
Number of complaints of sexual harassment received	NIL
Number of complaints disposed	NIL
Number of complaints pending as on March 31, 2026	NIL
Number of cases pending for more than 90 days	NIL

Yours Director further confirm that your company is compliant with the applicable provisions of the Maternity Benefit Act, 1961 and has policies, systems and processes in place to ensure ongoing compliance.

DIRECTORS' RESPONSIBILITY STATEMENT

Your Directors confirm:

1) that in the preparation of annual accounts for the year ended March 31, 2026, the applicable accounting standards read with the requirements set out under Schedule III to the Act have been followed along with proper explanation relating to material departures and there are no material departures from the same;

2) that the Directors have selected such accounting policies and applied them

consistently and made judgements and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the company at the end of the financial year 2025-2026 and of the profit and loss of the company for that period;

3) that the Directors have taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of this Act for safeguarding the assets of the company and for preventing and detecting fraud and other irregularities;

4) that the Directors have prepared the annual accounts on a going concern basis;

5) that the Directors have devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems were adequate and operating effectively.

ACKNOWLEDGEMENTS

Your Directors wish to express their gratitude to the Department of Biotechnology (DBT) for technical and financial support extended to your company. They also wish to thank the institutions who have been the sources of technologies, various Central and State Government departments, agencies and international sponsors including Ministry of Environment, Forest and Climate Change (MoEF&CC), Indian Council of Agricultural Research (ICAR), Council of Scientific and Industrial Research (CSIR), Ministry of Micro, Small & Medium Enterprises (MSME), Biotechnology Industry Research Assistance Council (BIRAC), United Nations Development Programme (UNDP), United Nations Environment Programme (UNEP), Agriculture & Food Systems Institute (AFSI), Department of Science and Technology (DST), Indian Council of Medical Research (ICMR), the financial institutions including IDBI Bank Limited, IFCI Limited, ICICI Bank, IFCI Venture Capital Limited and Specified Undertaking of Unit Trust of India (SUUTI) for their continued support and guidance and all the company's clients for the opportunity to serve them. Your Directors also place on record their appreciation of the devoted services rendered by the employees of the company.

For and on behalf of the Board of Directors

Date: 13.07.2026 **(Dr. Shekhar C Mande)**

Place: New Delhi **Chairman**

DIN-10083454

Annex A

AOC-2

(Pursuant to Clause (h) of Sub-Section (3) of Section 134 of the Act and Rule 8(2) of the Companies (Accounts) Rules, 2014)

Form for disclosure of particulars of contracts/arrangements entered into by the company with related parties referred to in Sub-Section (1) of Section 188 of the Companies Act, 2013 including certain arms length transactions under third proviso thereto

i. Details of contracts or arrangsements or transactions not at arm's length basis

SN	Name of the related party and nature of relationship	Nature of contracts/ arrangements/ transactions	Duration of the contracts / arrangements/ transactions	Salient terms of the contracts or arrangements or transactions including the value, if any	Justification for entering into such contracts or arrangements or transactions	Date of approval by the Board	Amount paid as advances, if any:	Date on which the special resolution was passed in general meeting as required under first proviso to section 188
NIL								

ii. Details of material contracts or arrangement or transactions at arm's length basis

SN	Name of the related party and nature of relationship	Nature of contracts/ arrangements/transactions	Duration of the contracts / arrangements/ transactions	Salient terms of the contracts or arrangements or transactions including the value, if any:	Date(s) of approval by the Board, if any:	Amount paid as advances, if any:
1.	Dr. Purnima Sharma Sh. Mukesh Gupta KMPs	Payment of salaries	N.A.	N.A.	N.A.	N.A.
2.	IDBI Bank Limited Investing company/ enterprise having significant influence over the company.	Banking transactions: Currents accounts and term deposits	N.A.	N.A.	N.A.	N.A.

INDEPENDENT AUDITORS' REPORT

To the Members of Biotech Consortium India Limited

Report on the Audit of Financial Statements

Opinion

We have audited the accompanying financial statements of Biotech Consortium India Limited ("the Company"), which comprise the balance sheet as at March 31, 2026, the Statement of Profit and Loss and statement of cash flows for the year then ended, and notes to the financial statements, including a summary of significant accounting policies and other explanatory information. (hereinafter referred to as the "financial statement").

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid financial statements give the information required by the Companies Act, 2013 ("The Act") in the manner so required and give a true and fair view in conformity with the Accounting Standard prescribed under Section 133 of the Act and other accounting principles generally accepted in India, of the state of affairs of the Company as at March 31, 2026, the profit and its cash flows for the year ended on that date.

Basis for opinion

We conducted our audit of the financial statements in accordance with the standards on auditing specified under section 143(10) of the Companies Act, 2013. Our responsibilities under those Standards are further described in the auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the Company in accordance with the code of ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and ICAI's code of ethics. We believe the Audit evidence obtained by us is sufficient and appropriate to provide a basis for our audit opinion on the financial statement.

Emphasis of Matter

We draw attention to the note no. 22.8 of the financial statements in respect of balances of receivables, project advances, sundry debtors and creditors which are subject to their confirmations. We have been informed that the amount receivable from Government agencies and balances of project advance accounts cannot be confirmed due to the different method of accounting employed by these agencies. The balances in project advances represent unspent amount of Rs.117.41 lacs (P.Y Rs. 234.68 lacs) from the project fund granted by them and the same are utilized/spent for the project as per sanction order and balances due to them cannot be confirmed. Likewise, sundry debtors of Rs.294.66 lacs (P.Y. 270.02 lacs) includes dues from govt. agencies/Institutions and the same are also not confirmed. We have not modified our report on this.

We draw the attention to the note no .21.2 of the financial statement where the company has shown a sum of Rs.10.39 lacs (P.Y. Rs. 9.37 lacs) due to MSME Creditors and the same is identified by the management but no Interest is shown as payable to the creditors which are due for more than 45 days since the company has clarified that the interest is not payable to them as per terms of understanding/ contracts with the creditors. We have not modified our report on this.

Information other than the financial statements and auditor's report thereon

The Company's board of directors is responsible for the other information. The other information comprises the information included in the Board's Report including Annexures to Board's Report, but does not include the financial statements and our auditor's report thereon.

Our opinion on the financial statements does not cover the other information and we do not express any form of assurance/ conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained during the course of our audit or otherwise appears to be materially misstated.

If based on the work, we have performed, we conclude that there is a material misstatement of this other information we are required to report that fact. We have nothing to report in this regard.

Management's responsibility for the financial statements

The Company's board of directors are responsible for the matters stated in section 134 (5) of the Act with respect to the preparation of these financial statements that give a true and fair view of the financial position, financial performance and cash flows of the Company in accordance with the accounting principles generally accepted in India, including the accounting standards specified under section 133 of the Act.

This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statement that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The board of directors are also responsible for overseeing the Company's financial reporting process.

Auditor's responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists.

Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal financial control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Companies Act, 2013, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls system in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

Materiality is the magnitude of misstatements in the standalone financial statements that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the standalone financial statements may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the standalone financial statements.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the financial statements of the current period. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

Report on other legal and regulatory requirements

As required by the Companies (Auditor's Report) Order, 2020 ("the Order"), issued by the Central Government of India in terms of sub-section (11) of section 143 of the Companies Act, 2013, we give in "Annexure "A" a statement on the matters specified in paragraphs 3 and 4 of the Order.

As required by Section 143(3) of the Act, we report that:

a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit;

b) In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books;

c) The balance sheet, the statement of profit and loss and the cash flow statement dealt with by this report are in agreement with the books of account;

d) In our opinion, the aforesaid financial statements comply with the accounting standards specified under section 133 of the Act, read with rule 7 of the Companies (Accounts) Rules, 2014;

e) On the basis of the written representations received from the directors as on March 31, 2026 taken on record by the board of directors, none of the directors is disqualified as on March 31, 2026 from being appointed as a director in terms of Section 164 (2) of the Act;

f) With respect to the adequacy of the internal financial controls over financial reporting of the Company and the operating effectiveness of such controls, refer to our separate report in "Annexure B". Our report expresses an unmodified opinion on the adequacy and operating effectiveness of the Company's internal financial controls over financial reporting;

g) With respect to the other matters to be included in the Auditor's Report in accordance with the requirements of section 197 (16) of the Act, as amended, in our opinion and to the best of our information and according to the explanations given to us, the remuneration paid by the Company to its directors during the year is in accordance with the provisions of section 197 of the Act; and

h) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us;

   i. Pending litigations and their impact are disclosed in the financial statement;

   ii. The Company did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses; and

   iii. There has been no delay in transferring amounts, required to be transferred, to the Investor Education and Protection Fund by the Company.

   iv. (a) The Management has represented that, to the best of its knowledge and belief, other than as disclosed in the notes to the accounts, no funds have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the Company to or in any other person(s) or entity(ies), including foreign entities ("Intermediaries"), with the understanding, whether recorded in writing or otherwise, that the Intermediary shall, whether, directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Company ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.

(b) The Management has represented, that, to the best of its knowledge and belief, other than as disclosed in the notes to the accounts, no funds have been received by the Company from any person(s) or entity(ies), including foreign entities ("Funding Parties"), with the understanding, whether recorded in writing or otherwise, that the Company shall, whether, directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.

(c) Based on such audit procedures that have been considered reasonable and appropriate in the circumstances, nothing has come to our notice that has caused us to believe that the representations under sub-clause (i) and (ii) of Rule 11(e), as provided in (a) and (b) above, contain any material misstatement.

v. (a) The Company has neither declared nor paid any dividend during the year.

(b) The Board of Director of the Company have not proposed any dividend during the year.

vi. Based on our examination which included test checks, the Company has used accounting software for maintaining its books of account for the financial year ended 31st March, 2026 which has a feature of recording audit trail (edit log) facility and the same has operated throughout the year for all relevant transactions recorded in the software. Further, during the course of our audit we did not come across any instance of audit trail feature being tampered with.

As per proviso to Rule 3(1) of the Companies (Accounts) Rules, 2014, reporting under Rule 11(g) of the Companies (Audit and Auditors) Rules, 2014 on preservation of audit trail as per the statutory requirements for record retention has been maintained by the company for the financial year ended 31st March, 2026.

For Aggarwal Vineeta & Co.

Chartered Accountants

FRN: 011645N

Suresh Aggarwal

Place: New Delhi **(Partner)**

Date: 13/07/2026 **Membership No.: 087280**

UDIN -26087280NPBWNY7801

Annexure "A" to the Independent Auditor's Report

Referred to in paragraph 1 under 'Report on other legal and regulatory requirements' section of our report to the members of **Biotech Consortium India Limited** for the year ended 31st March, 2026

1. In respect of the Company's Property, Plant and Equipment (PPE) and Intangible assets:

   a) The Company has maintained proper records showing full particulars, including quantitative details and situation of Plant Property & Equipment (PPE) and intangible assets.

   b) The Plant Property & Equipment of the Company were physically verified in full by the management during the year. According to the information and explanations given to us and as examined by us, no material discrepancies were noticed on such verification.

   c) According to the information, explanations given to us and the records examined by us, we report that the Company does not hold any freehold and leasehold immovable property in the name of the Company as at the balance sheet date.

   d) The Company has not revalued its PPE (including right-of-use assets) or intangible assets.

   e) No proceedings have been initiated or are pending against the Company for holding benami property under the Benami Transactions (Prohibition) Act, 1988.

2. The company do not have any inventory; hence paragraph 3(ii) of the order is not applicable.

3. According to information and explanation given to us, the company has not granted any loan, secured or unsecured to companies, firms, limited liability partnerships or other parties except staff loans and small investment of 20 equity shares. We further report that-

   a) No new staff loans and investments has been made during the year and outstanding amount of investment and staff loans is Rs. 0.19 lakhs and Rs. 0.88 lakhs respectively.

   b) The terms and conditions are not prejudicial to the company's interest

   c) The repayment of staff loan is regular.

   d) There is no overdue amount.

   e) No loan granted has fallen due and also not been renewed/extended or fresh loans granted to settle existing loans.

   f) No loans/advances have been granted to promoters or related parties.

4. In our opinion and according to information and explanation given to us, the company has duly complied with provision of section 185 and 186 of the Companies Act, 2013.

5. In our opinion and according to the information and explanations given to us, the company has not accepted any deposits and accordingly paragraph 3 (v) of the order is not applicable.

6. The Central Government of India has not prescribed the maintenance of cost records under sub-section (1) of section 148 of the Act for any of the activities of the company and accordingly paragraph 3 (vi) of the order is not applicable.

7. In respect of statutory dues:

   According to the information and explanations given to us and on the basis of our examination of the records of the Company, amounts deducted/ accrued in the books of account in respect of undisputed statutory dues including provident fund, employees' state insurance, income-tax, goods and service tax, duty of customs, and other material statutory dues have been generally regularly deposited during the year by the company with the appropriate authorities.

According to the information and explanations given to us, no undisputed amounts payable in respect of provident fund, employees' state insurance, income-tax, , goods and service tax, duty of customs, and other material statutory dues were in arrears as at March 31, 2026 for a period of more than six months from the date they became payable.

According to the information and explanations given to us and the records of the company examined by us, there are no dues of income-tax and goods and service tax, duty of customs, duty of excise and value added tax which have not been deposited on account of any dispute, except the following:

S. No.	Statute	Nature of dues	Amount un-paid (Rs.)	Assessment year/Financial Year to which the amount relates	Forum where the dispute/ application is pending
1	Income Tax Act, 1961	Demand raised u/s 115WE	2,02,078/-*	2009-10	DCIT, Circle 5(1)
2.	Income Tax Act, 1961	Demand raised u/s 143(1)	9,00,668/-*	2006-07	DCIT, Circle 5(1)
3.	Income Tax Act, 1961	Demand raised u/s 143(1)(a)	78,450/-*	2019-20	DCIT, Circle 5(1)
4.	Income Tax Act, 1961	Demand raised u/s 143(1)(a)	64,770/-*	2018-19	DCIT, Circle 5(1)
5.	Income Tax Act, 1961	TDS Demand	83,460/-*	2008-09 to 2018-19	DCIT, Circle 73(1)
6.	CGST Act 2017	Demand raised u/s 73 of CGST Act	2,80,150/-	2017-18	GST Appellate Authority

**Application for rectification is yet to be disposed off by the Income Tax Department.*

8. According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not surrendered or disclosed any transactions, previously unrecorded as income in the books of account, in the tax assessments under the Income-tax Act, 1961 as income during the year.

9. In our opinion and according to the information and explanations given to us, the company has no outstanding dues to any financial institutions or banks or any government or any debenture holders during the year. Accordingly, paragraph 3 (ix) of the order is not applicable.

10. The Company has not raised any money by way of initial public offer or further public offer (including debt instruments) and has not taken any term loans during the year. Accordingly, paragraph 3 (x) of the order is not applicable.

11. To the best of our knowledge and according to the information and explanations given to us, considering the principles of materiality outlined in Standards on Auditing, we report that no fraud by the Company or on the Company has been noticed or reported during the course of the audit.

    Further, no report under Section 143(12) has been filed by the auditors in Form ADT-4 as prescribed under Rule 13 of the Companies (Audit and Auditors) Rules, 2014 against the company. And, no whistle-blower complaints have been received during the year by the company.

12. The Company is not a Nidhi Company and accordingly, paragraph 3 (xii) of the order is not applicable to the Company.

13. According to the information and explanations given to us and based on our examination of the records of the company, transactions with the related parties are in compliance with Section 177 and Section 188 of the Companies Act. Wherever applicable, the details of such transactions have been disclosed in the financial statements as required by the applicable accounting standards.

14. Based on information and explanations provided to us and our audit procedures, in our opinion, the internal audit system as required under Section 138 of the Companies Act is not applicable to the company during the year.

15. According to the information and explanations given to us and based on our examination of the records of the company, the company has not entered into non- cash transactions with directors or persons connected with them. Accordingly, paragraph 3 (xv) of the order is not applicable.

16. According to the information and explanations given to us and based on our examination of the records of the company, the company is not required to be registered under section 45-IA of the Reserve Bank of India Act 1934. Accordingly, paragraph 3 (xvi) of the order is not applicable

17. The Company has not incurred cash losses in the current and in the immediately preceding financial year. Accordingly, paragraph 3 (xvii) of the order is not applicable.

18. There has been no resignation of the statutory auditors during the year. Accordingly, clause 3(xviii) of the Order is not applicable.

19. According to the information and explanations given to us and on the basis of the financial ratios, ageing and expected dates of realization of assets and payment of liabilities, other information accompanying the financial statements, our knowledge of the Board of Directors and management plans and based on our examination of the evidence supporting the assumptions, nothing has come to our attention, which causes us to believe that any material uncertainty exists as on the date of the audit report that the Company is not capable of meeting its liabilities existing at the date of balance sheet as and when they fall due within a period of one year from the balance sheet date.

    We, however, state that this is not an assurance as to the future viability of the Company. We further state that our reporting is based on the facts up to the date of the audit report and we neither give any guarantee nor any assurance that all liabilities falling due within a period of one year from the balance sheet date, will get discharged by the Company as and when they fall due.

20. In our opinion and according to the information and explanations given to us, company do not fall under the condition specified under Section 135 of the Companies Act, 2013 and accordingly, this clause of the Order is not applicable.

21. Clause 3(xxi) is not applicable to the company.

For Aggarwal Vineeta & Co.

Chartered Accountants

FRN: 011645N

Suresh Aggarwal

Place: New Delhi **(Partner)**

Date: 13/07/2026 **Membership No. : 087280**

UDIN -26087280NPBWNY7801

Annexure "B" to the Independent Auditor's Report

Report on the internal financial controls over financial reporting under clause (i) of sub – section 3 of section 143 of the Companies Act, 2013 ("the Act")

We have audited the internal financial controls over financial reporting of Biotech Consortium India Limited ("the Company") as at March 31, 2026, in conjunction with our audit of the financial statements of the Company for the year ended on that date.

Management's responsibility for internal financial controls

The Board of directors of the Company is responsible for establishing and maintaining internal financial controls based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls over Financial Reporting issued by the Institute of Chartered Accountants of India. These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records and the timely preparation of reliable financial information, as required under the Companies Act, 2013.

Auditors' responsibility

Our responsibility is to express an opinion on the internal financial controls over financial reporting of the Company based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting (the "Guidance Note") issued by the Institute of Chartered Accountants of India and the standards on auditing prescribed under Section 143 (10) of the Companies Act, 2013, to the extent applicable to an audit of internal financial controls. Those standards and the guidance note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting were established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system over financial reporting and their operating effectiveness. Our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement in the financial statements, whether due to fraud or error.

We believe that the audit evidence, we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company's internal financial control system over financial reporting.

Meaning of internal financial controls over financial reporting

A company's internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial control over financial reporting includes those policies and procedures that (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Limitations of internal financial controls over financial reporting

Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management of override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Opinion

In our opinion and according to the information and explanations given to us, the Company has, in all material respects, an adequate internal financial control system over financial reporting and such internal financial controls over financial reporting were operating effectively as at March 31, 2026, based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India.

For Aggarwal Vineeta & Co.

Chartered Accountants

FRN: 011645N

Suresh Aggarwal

Place: New Delhi **(Partner)**

Date: 13/07/2026 **Membership No. : 087280**

UDIN -26087280NPBWNY7801

BALANCE SHEET AS AT 31ST MARCH 2026

(Rs. in lacs)

	Particulars	Note No.	As at 31 March, 2026	As at 31 March, 2025
A	EQUITY AND LIABILITIES			
1	**Shareholders' Funds**			
a	Share Capital	1	537.00	537.00
b	Reserves and Surplus	2	2,445.94	2,433.25
			2982.94	**2970.25**
2	**Non-Current Liabilities**			
a	Long-Term Provisions	3	221.32	211.69
b	Other Long-Term Liabilities	4	117.41	114.86
			338.73	**326.55**
3	**Current Liabilities**			
a	Trade Payables	5		
	Due to MSME		10.39	9.37
	Due to other than MSME		18.92	9.64
b	Other Current Liabilities	6	119.23	245.51
c	Short Term Provisions	7	61.06	98.04
			209.60	**362.56**
	Total		**3531.27**	**3659.36**
B	ASSETS			
1	Non-Current Assets			
a	Property, Plant & Equipment and Intangible Assets			
(i)	Property, Plant & Equipment	8	5.16	5.59
b	Non-Current Investments	9	0.19	0.19
c	Deferred Tax Assets (net)	22.5	16.74	20.59
d	Long-Term Loans and Advances	10	0.88	1.35
e	Other Non-Current Assets	11	3089.68	2923.67
			3112.65	**2951.39**
2	**Current Assets**			
a	Trade Receivables	12	294.66	270.02
b	Cash and Cash Equivalents	13	84.79	391.54
c	Short-Term Loans and Advances	14	39.17	46.41
			418.62	**707.97**
	Total		**3,531.27**	**3,659.36**

See accompanying notes (1-23) forming part of the financial statements

In terms of our report attached.
For Aggarwal Vineeta & Co.
Chartered Accountants
FRN: 011645N
(Suresh Aggarwal)
Partner
M.N. 087280

UDIN -26087280NPBWNY7801

Place: New Delhi
Date: 13/07/2026

For and on behalf of the Board of Directors

(Dr. Shekhar C Mande)
Chairman
DIN-10083454

(Dr.Purnima Sharma)
Managing Director
DIN-01082972

(Mukesh Gupta)
AGM (Finance) & Company Secretary

STATEMENT OF PROFIT AND LOSS
FOR THE YEAR ENDED 31ST MARCH, 2026

(Rs. in lacs)

	Particulars	Note No.	For the year ended 31 March, 2026	For the year ended 31 March, 2025
1	Revenue from Operations	15	414.33	418.08
2	Other Income	16	198.10	193.84
3	**Total Income (1+2)**		**612.43**	**611.92**
4	**Expenses**			
a	Employee Benefits Expense	17	263.34	292.49
b	Depreciation and Amortisation Expense	8	0.24	1.07
c	Depreciation on Assets Funded by Grants	8A	0.00	(0.51)
d	Other Expenses	18	334.88	314.04
5	**Total Expenses (a to d)**		**598.46**	**607.09**
6	**Profit before exceptional and extraordinary items and tax (3-5)**		**13.97**	**4.83**
7	Exceptional and Extraordinary items	21.5	10.75	6.11
8	**Profit / (Loss) Before Tax (6+7)**		**24.72**	**10.94**
9	Tax Expense:			
a	Current Tax Expense for Current Year		8.12	4.17
b	Tax Provision of previsous year no longer required		0.05	3.75
c	Deferred Tax (Assets/Liabilities)		3.85	(2.08)
			12.02	**5.84**
10	**Profit / (Loss) for the year (8-9)**		**12.70**	**5.10**
11	**Earnings per share (of Rs. 10/- each):**			
	Basic	22.4	0.24	0.09
	Diluted		0.24	0.09
	See accompanying notes (1-23) forming part of the financial statements			

In terms of our report attached.
For Aggarwal Vineeta & Co.
Chartered Accountants
FRN: 011645N
(Suresh Aggarwal)
Partner
M.N. 087280

UDIN -26087280NPBWNY7801

Place: New Delhi
Date: 13/07/2026

For and on behalf of the Board of Directors

(Dr. Shekhar C Mande)
Chairman
DIN-10083454

(Dr.Purnima Sharma)
Managing Director
DIN-01082972

(Mukesh Gupta)
AGM (Finance) & Company Secretary

CASH FLOW STATEMENT FOR THE YEAR 2025-26

(Rs. in lacs)

	Particulars	2025-26		2024-25	
A	CASH FLOW FROM OPERATING ACTIVITIES				
	Net Profit before Tax as per Statement of Profit and Loss		**24.72**		**10.94**
	Adjusted for:				
	Depreciation / Amortisation Expenses	0.24		0.56	
	Dividend Income	0.00		0.00	
	Interest Income	(196.81)		(193.14)	
	Other non-operating income	(1.29)		(0.70)	
	Increase in Provision for Employee Benifits	9.63		(24.05)	
	Increase in Project Advantage	2.55		14.78	
	Decrease in Loans and Advances To Staff	0.47		8.67	
			(185.21)		(193.88)
	Operating Profit/(Loss) before Working Capital Changes		**(160.49)**		**(182.94)**
	Adjusted for:				
	Trade Receivables	(24.65)		21.15	
	Short-Term Loans and Advances	7.24		(9.33)	
	Trade Payables	10.30		(27.90)	
	Other Current Liabilities	(126.28)		131.90	
	Short Term Provisions	(36.98)		2.58	
			(170.37)		**118.40**
	Cash generated from Operations		**(330.86)**		**(64.54)**
	Taxes paid (Net)		(8.17)		(7.93)
	Net cash flow from / (used in) operating activities (A)		**(339.03)**		**(72.47)**
B	CASH FLOW FROM INVESTING ACTIVITIES				
	Proceeds from Disposal (Net)	0.19		0.06	
	Sale of Non Current Investments	0.00		0.00	
	Increase in other Non Current Assests	(166.01)		37.18	
	Interest Income	196.81		193.14	
	Dividend Income	0.00		0.00	
	Other non-operating income	1.29		0.70	
	Net Cash generated from (Used in) Investing Activities (B)		**32.28**		**231.08**
C	CASH FLOW FROM FINANCING ACTIVITIES				
	Net Cash generated from /(Used in) Financing Activities		0.00		0.00
	Net (Decrease) in Cash and Cash Equivalents		(306.75)		158.61
	Opening Balance of Cash and Cash Equivalents		391.54		232.93
	Closing Balance of Cash and Cash Equivalents (Refer Note 13 to Financial Statements)		84.79		391.54

In terms of our report attached.
For Aggarwal Vineeta & Co.
Chartered Accountants
FRN: 011645N
(Suresh Aggarwal)
Partner
M.N. 087280
UDIN -26087280NPBWNY7801

For and on behalf of the Board of Directors

(Dr. Shekhar C Mande)
Chairman
DIN-10083454

(Dr.Purnima Sharma)
Managing Director
DIN-01082972

(Mukesh Gupta)
AGM (Finance) & Company Secretary

Place: New Delhi
Date: 13/07/2026

NOTES FORMING PART OF THE FINANCIAL STATEMENTS

Note 1 Share Capital

Particulars	As at 31 March, 2026		As at 31 March, 2025	
	Number of shares	Rs. in lacs	Number of shares	Rs. in lacs
(a) Authorised				
Equity shares of Rs. 10 each with voting rights	1,00,00,000	1,000.00	1,00,00,000	1,000.00
(b) Issued				
Equity shares of Rs.10 each with voting rights	53,70,027	537.00	53,70,027	537.00
(c) Subscribed and fully paid up				
Equity shares of Rs.10 each with voting rights	53,70,027	537.00	53,70,027	537.00
Total		**537.00**		**537.00**

Particulars

Notes: (i) Reconciliation of the number of shares and amount outstanding at the beginning and at the end of the reporting period:

Particulars	Opening Balance	Fresh issue	Bonus	ESOP	Conversion	Buy back	Other changes (give details)	Closing Balance
Equity shares with voting rights								
Year ended 31 March, 2026								
- Number of shares	53,70,027	0.00	0.00	0.00	0.00	0.00	0.00	53,70,027
- Amount (Rs. in lacs)	537.00	0.00	0.00	0.00	0.00	0.00	0.00	537.00
Year ended 31 March, 2025								
- Number of shares	53,70,027	0.00	0.00	0.00	0.00	0.00	0.00	53,70,027
- Amount (Rs. in lacs)	537.00	0.00	0.00	0.00	0.00	0.00	0.00	537.00

(ii) The company has only one class of equity shares having a par value of Rs. 10 per share. Each Shareholder is eligible for one vote per share. The dividend proposed by the Board of Directors is subject to the approval of Members except in case of interim dividend.In the event of liquidation, the equity shareholders are eligible to receive the remaining assets of the company after distribution of all preferential amounts, in proportion of their shareholding.

(iii) Details of shares held by promoters and each shareholder holding more than 5% shares

Class of shares / Name of shareholder	As at 31 March, 2026			As at 31 March, 2025		
	Number of shares held	% holding in that class of shares	% Change during the year	Number of shares held	% holding in that class of shares	% Change during the year
Equity shares with voting rights						
IDBI Bank Limited	15,00,004	27.93	-	15,00,004	27.93	-
IFCI Limited	10,00,001	18.62	-	10,00,001	18.62	-
IDBI Trusteeship Services Ltd. (ICICI Strategic Investments Fund)	0	0.00	-100.00	10,00,000	18.62	-
Administrator of the Specified Undertaking of the Unit Trust of India	3,00,000	5.59	00.00	3,00,000	5.59	-
ICICI Bank Limited	10,00,001	18.62	100.00	1	0.00	-
IFCI Venture Capital Funds Ltd.	2,00,001	3.72	-	2,00,001	3.72	-

NOTES FORMING PART OF THE FINANCIAL STATEMENTS

Note 2 Reserves and Surplus (Rs. in lacs)

Particulars	As at 31 March, 2026	As at 31 March, 2025
(a) Deferred Grant Account		
Opening balance	2.85	3.69
Add: Additions during the year (Fixed assets purchased from the grants received during the year)	0.00	0.00
Less: Transferred during the year including Depreciation on assets wpurchased out of grants	0.01	0.84
Closing balance	**2.84**	**2.85**
(b) Surplus / (Deficit) in Statement of Profit and Loss		
Opening balance	2,430.40	2,425.30
Add: Profit / (Loss) for the year	12.70	5.10
Closing balance	**2,443.10**	**2,430.40**
Total (a+b)	**2,445.94**	**2,433.25**

Note 3 Long-Term Provisions (Rs. in lacs)

Particulars	As at 31 March, 2026	As at 31 March, 2025
Provision for employee benefits:		
(i) Provision for gratuity (Refer Note 22.2.a)	117.81	114.31
(ii) Provision for leave encashment (Refer Note 22.2.b)	103.51	97.38
Total	**221.32**	**211.69**

Note 4 Other Long-Term Liability (Rs. in lacs)

Particulars	As at 31 March, 2026	As at 31 March, 2025
(i) Project/Customer Advances	117.41	114.86
Total	**117.41**	**114.86**

Note 5 Trade Payables (Rs. in lacs)

Particulars	As at 31 March, 2026	As at 31 March, 2025
Trade payables (Refer Note 21.2)		
(i) MSME		
Less than 1 year (Unbilled Rs. 1.57 lacs (PY- Rs. 4.45 lacs)	6.42	7.54
1-2 years	2.34	0.33
2-3 years	0.33	0.54
More than 3 Years	1.30	0.96
(ii) Others		
Less than 1 year	14.67	5.47
1-2 years	0.71	-
2-3 years	-	4.17
More than 3 Years	3.54	-
(iii) Disputed Dues (MSME)		
Less than 1 year	-	-
1-2 years	-	-
2-3 years	-	-
More than 3 Years	-	-
(iv) Disputed Dues (Others)		
Less than 1 year	-	-
1-2 years	-	-
2-3 years	-	-
More than 3 Years	-	-
Total	**29.31**	**19.01**

NOTES FORMING PART OF THE FINANCIAL STATEMENTS

Note 6 Other Current Liabilities

(Rs. in lacs)

Particulars	As at 31 March, 2026	As at 31 March, 2025
Other payables		
(i) Statutory remittances (Contributions to PF, ESIC, GST, TDS etc.)	17.49	44.80
(ii) Project/Customer Advances	0.00	119.82
(iii) Creditors for Others	65.90	26.93
(iv) Outstanding Expenses	35.84	53.96
Total	**119.23**	**245.51**

Note 7 Short Term Provisions

(Rs. in lacs)

Particulars	As at 31 March, 2026	As at 31 March, 2025
Provision for Income Tax	8.12	4.17
Provision for gratuity (Refer Note 22.2.a)	22.57	41.75
Provision for leave encashment (Refer Note 22.2.b)	30.37	52.12
Total	**61.06**	**98.04**

NOTES FORMING PART OF THE FINANCIAL STATEMENTS

Note 8 Fixed Assets (Rs. in lacs)

Property, Plant & Equip-ment-Owned	Gross block				Accumulated depreciation and impairment				Net block	
	Balance as at 1 April, 2025	Additions	Disposals	Balance as at 31 March, 2026	Balance as at 1 April, 2025	Depreciation / amortisation expense for the year	Depreciation / amortisation on assets disposed off	Balance as at 31 March, 2026	Balance as at 31 March, 2026	Balance as at 31 March, 2025
(a) Plant & Machinery-										
Data Centre Equipments*	68.56	0.00	0.00	68.56	66.95	0.00	0.00	66.95	1.61	1.61
(b) Furniture and Fixtures -										
Furniture & Fixtures	36.64	0.00	0.00	36.64	35.73	0.00	0.00	35.73	0.91	0.91
Furniture & Fixtures (NCS-TCP) *	0.11	0.00	0.00	0.11	0.11	0.00	0.00	0.11	0.00	0.00
Furniture & Fixtures (UNEP-GEF) *	0.19	0.00	0.00	0.19	0.19	0.00	0.00	0.19	0.00	0.00
(c) Office Equipments -										
Office Equipments (Others)	30.89	0.00	0.19	30.70	29.58	0.24	0.00	29.82	0.88	1.31
Office Equipments (BITP)*	0.81	0.00	0.00	0.81	0.81	0.00	0.00	0.81	0.00	0.00
Office Equipments (Data Centre)*	11.83	0.00	0.00	11.83	11.67	0.00	0.00	11.67	0.16	0.16
Office Equipments (IPR CELL) *	2.16	0.00	0.00	2.16	2.14	0.00	0.00	2.14	0.02	0.02
Office Equipments (NCS-TCP) *	0.46	0.00	0.00	0.46	0.46	0.00	0.00	0.46	0.00	0.00
Office Equipments (RCGM) *	1.61	0.00	0.00	1.61	1.59	0.00	0.00	1.59	0.02	0.02
Office Equipments (IGMORIS) *	0.30	0.00	0.00	0.30	0.30	0.00	0.00	0.30	0.00	0.00
Office Equipments (PMU under NCS-TCP) *	0.48	0.00	0.00	0.48	0.48	0.00	0.00	0.48	0.00	0.00
Office Equipments (UNEP GEF) *	2.17	0.00	0.00	2.17	2.17	0.00	0.00	2.17	0.00	0.00
Office Equipments (TTO) *	0.68	0.00	0.00	0.68	0.65	0.00	0.00	0.65	0.03	0.03
(d) Others -Computers -										
Computer Systems	30.50	0.00	0.00	30.50	29.98	0.00	0.00	29.98	0.52	0.52
Computer Systems-(BITP) *	4.14	0.00	0.00	4.14	4.14	0.00	0.00	4.14	0.00	0.00
Computer Systems-(BIITP) *	0.74	0.00	0.00	0.74	0.74	0.00	0.00	0.74	0.00	0.00
Computer Systems-(BITP_NES) *	0.37	0.00	0.00	0.37	0.37	0.00	0.00	0.37	0.00	0.00
Computer Systems-(IGMORIS) *	8.21	0.00	0.00	8.21	8.21	0.00	0.00	8.21	0.00	0.00
Computer Systems-(IPR Cell) *	3.32	0.00	0.00	3.32	3.32	0.00	0.00	3.32	0.00	0.00
Computer Systems-(NCS-TCP) *	0.70	0.00	0.00	0.70	0.70	0.00	0.00	0.70	0.00	0.00
Computer Systems-(NCS Mgt. Cell) *	10.44	0.00	0.00	10.44	10.13	0.00	0.00	10.13	0.31	0.31
Computer Systems-(Placement Project) *	0.85	0.00	0.00	0.85	0.85	0.00	0.00	0.85	0.00	0.00
Computer Systems-(PMU under NCS-TCP) *	3.13	0.00	0.00	3.13	3.13	0.00	0.00	3.13	0.00	0.00
Computer Systems-(TTO) *	12.41	0.00	0.00	12.41	11.79	0.00	0.00	11.79	0.62	0.62
Computer Systems-(RCGM) *	6.14	0.00	0.00	6.14	6.14	0.00	0.00	6.14	0.00	0.00
Computer Systems-(Award Programme) *	0.35	0.00	0.00	0.35	0.35	0.00	0.00	0.35	0.00	0.00
Computer Systems-(UNEP-GEF) *	10.77	0.00	0.00	10.77	10.69	0.00	0.00	10.69	0.08	0.08
Total	**248.96**	**0.00**	**0.19**	**248.77**	**243.37**	**0.24**	**0.00**	**243.61**	**5.16**	**5.59**
Previous year	**249.34**	**0.00**	**0.38**	**248.96**	**242.30**	**1.07**	**0.00**	**243.37**	**5.59**	**7.04**

***Above assets represents assets purchased out of grants.**

NOTES FORMING PART OF THE FINANCIAL STATEMENTS

Note 8A Fixed Assets (contd.) (Rs. in lacs)

A.	Depreciation and amortisation relating to continuing operations:		
	Particulars	**For the year ended 31 March, 2026**	**For the year ended 31 March, 2025**
	Depreciation and amortisation for the year on tangible assets as per Note 8	0.24	1.07
	Less: Depreciation and amortisation for the year on assets funded by grants as per Note 8	0.00	0.51
	Depreciation and amortisation relating to continuing operations	**0.24**	**0.56**

Note 9 Non-Current Investments

	Particulars	As at 31 March, 2026				As at 31 March, 2025			
		No. of Units	Face Value per unit (Rs.)	Cost of Invest-ments (Rs. in lacs)	Market Value as on 31.03.26 (Rs. in lacs)	No. of Units	Face Value per unit (Rs.)	Cost of Invest-ment (Rs. in lacs)	Market Value as on 31.03.25 (Rs. in lacs)
	Other investments (At cost) (Long Term)								
(a)	**Investment in equity instruments**								
	DLF	20.00	10.00	0.19	0.13	20.00	10.00	0.19	0.16
	Total			**0.19**	**0.13**			**0.19**	**0.16**
	Less: Provision for diminution in value of investments			0.00				0.00	
	Total			**0.19**				**0.19**	
	Aggregate amount of quoted investments			0.19				0.19	
	Aggregate market value of listed and quoted investments			0.13				0.16	

NOTES FORMING PART OF THE FINANCIAL STATEMENTS

Note 10 Long-Term Loans and Advances (Rs. in lacs)

Particulars	As at 31 March, 2026	As at 31 March, 2025
Loans and advances to staff (Secured, considered good)	0.88	1.35
Total	**0.88**	**1.35**

Note 11 Other Non-Current Assets (Rs. in lacs)

Particulars	As at 31 March, 2026	As at 31 March, 2025
Security Deposits (Unsecured, considered good) including earnest money of Rs. 02.00 lacs(previous year Rs. 03.00 lacs)	48.31	49.31
Gratuity Fund	157.90	164.74
Leave Encashment Fund	89.92	88.92
Income Tax Refund	44.33	9.24
Bank deposits with more than twelve months maturity	2,739.75	2,593.62
Interest accured on Fixed Deposit with banks	9.47	17.84
Total	**3089.68**	**2923.67**

Note 12 Trade Receivables (Rs. in lacs)

Particulars	As at 31 March, 2026	As at 31 March, 2025
(i) Undisputed Trade receivables Considered good		
Less than six monhts	120.58	147.56
6 months to 1 year	38.06	41.75
1-2 years	22.30	30.78
2-3 years	8.39	8.69
More than 3 years	105.33	41.24
Total	**294.66**	**270.02**
(ii) Undisputed Trade receivables -considered doubtful		
Less than six monhts	0.00	0.00
6 months to 1 year	0.00	0.00
1-2 years	0.00	0.00
2-3 years	1.45	1.45
More than 3 years	14.85	14.85
Total	**16.30**	**16.30**
Less: Provision for doubtfuld debts	(16.30)	(16.30)
(iii) Disputed Trade receivables considered good	-	-
(iv) Disputed Trade receivables considered doubtful	-	-
Total	**294.66**	**270.02**

NOTES FORMING PART OF THE FINANCIAL STATEMENTS

Note 13 Cash and Cash Equivalents (Rs. in lacs)

Particulars	As at 31 March, 2026	As at 31 March, 2025
(a) Cash in hand including foreign currency of Rs. 1.30 lacs (PY- Rs. 1.07 lacs) (kept in safe locker)	1.75	1.43
(b) Balances with banks		
(i) In Current Accounts with scheduled banks	17.02	19.99
(ii) In Deposit Accounts with scheduled banks (Including Term Deposits of Rs. 9.06 lacs (Previous Year - Rs. 6.53 lacs) having lien in favour of HDFC Bank Limited towards bank gurantee provided to DBT, NII and RCB for execution of projects)	66.02	370.12
Total	**84.79**	**391.54**

Note 14 Short-Term Loans and Advances (Advances recoverable in cash or in kind and value to be received) (Rs. in lacs)

Particulars	As at 31 March, 2026	As at 31 March, 2025
(a) Prepaid expenses - Unsecured, considered good	3.41	6.10
(b) Income Tax (TDS)	35.62	39.59
(c) Others - Unsecured, considered good		
Other amount receivable	0.14	0.72
Total	**39.17**	**46.41**

Note 15 Revenue from Operations (Rs. in lacs)

	Particulars	For the year Ended 31 March, 2026	For the year 31 March, 2025
(a)	Sale of services		
(i)	Domestic Services (Includes IP Services of Rs. 50.57 lacs (PY- Rs. 64.94 lacs)	400.48	387.91
(ii)	Export Services	13.51	29.83
(b)	Other operating revenues	0.34	0.34
	Total	**414.33**	**418.08**

NOTES FORMING PART OF THE FINANCIAL STATEMENTS

Note 16 Other Income (Rs. in lacs)

	Particulars	For the year ended 31 March, 2026	For the year ended 31 March, 2025
(a)	Interest Income (Tax deducted at source - Rs. 18.92 lacs (Previous Year - Rs. 18.38 lacs) (Refer note no. (i) below)	196.81	193.14
	Interest Income on Project Funds		
	Interest received (Tax deducted at source - Rs. 0.70 lacs (Previous Year - Rs. 1.04 lacs)	9.85	10.69
	Less: Amount credited to Project Funds	(9.85)	(10.69)
(b)	Dividend income from long-term investments	0.00	0.00
(c)	Other non-operating income (net of expenses directly attributable to such income) (Refer Note (ii) below)	1.29	0.70
	Total	**198.10**	**193.84**

	Particulars	For the year ended 31 March, 2026	For the year ended 31 March, 2025
(i)	Interest income comprises:		
	Interest from banks on deposits	189.52	184.02
	Interest income from long term investments (Leave Encashment Fund)	7.22	7.75
	Interest on Income Tax Refund	-	1.02
	Interest on loans to staff	0.07	0.35
	Total - Interest income	**196.81**	**193.14**
(ii)	Other non-operating income comprises:		
	Prior period items (net) (Refer Note (iii) below)		
	Profit on sale of assets	0.00	0.07
	Miscellaneous income	1.29	0.63
	Total - Other non-operating income	**1.29**	**0.70**
(iii)	Details of Prior period items (net)		
	Prior period income	0.00	0.00
	Prior period expenses	0.00	0.00
	Total	0.00	0.00

NOTES FORMING PART OF THE FINANCIAL STATEMENTS

Note 17 Employee Benefits Expense (Rs. in lacs)

Particulars	For the year ended 31 March, 2026	For the year ended 31 March, 2025
Salaries and Wages (includes contractual salary of Rs. 32.55 lacs (PY: Rs. 6.13 lacs)	194.85	202.14
Managerial Remuneration	36.73	40.16
Insurance	5.39	5.13
Contributions to provident and other funds	20.57	22.78
Gratuity Premium	0.00	2.57
Leave Encashment Premium	4.34	3.15
Provision made for Leave Encashment	0.00	14.66
Staff Welfare Expenses	0.94	1.12
Ex Gratia	0.52	0.78
Total	**263.34**	**292.49**

NOTES FORMING PART OF THE FINANCIAL STATEMENTS

Note 18 Other Expenses (Rs. in lacs)

Particulars	For the year ended 31 March, 2026	For the year ended 31 March, 2025
Project Related Expenses	189.69	172.97
Technology Fees	21.47	12.17
Electricity Charges	4.11	6.57
Postage & Telecom Expenses	4.46	4.69
Books & Periodicals Expenses	0.39	0.32
Directors' Sitting Fee/Meeting Expenses	1.32	1.24
Bank Charges	0.30	0.11
Filing Fees	0.16	0.13
Reversal of GST input	2.02	1.68
Diwali Expenses	0.30	0.36
Rent Including Lease Rentals	80.70	78.00
Repairs & Maintenance - Others	10.59	8.75
Insurance	0.07	0.03
Travelling & Conveyance	10.14	14.44
Printing & Stationery	0.80	0.86
Provision for doubtful debts	0.00	1.92
Legal and Professional	5.14	1.44
Payments to Auditors (Refer Note (i) below)	1.75	2.75
Loss on foreign currency transactions and translation	1.05	0.75
Miscellaneous Expenses	0.42	4.86
Total	**334.88**	**314.04**

(Rs. in lacs)

Notes		
Particulars	**For the year ended 31 March, 2026**	**For the year ended 31 March, 2025**
(i) Payments to the auditors comprises (net of service tax input credit, where applicable):		
For other services	1.75	2.00
As auditors - statutory audit	0.00	0.50
For tax audit	0.00	0.25
Total	**1.75**	**2.75**

NOTES FORMING PART OF THE FINANCIAL STATEMENTS

Note	Particulars
19	**Corporate Information**
	'Biotech Consortium India Limited (BCIL) is a company promoted as an initiaitve of the Department of Biotechnology, Ministry of Science & Technology, Govt. of India (DBT) and financed by all India public financial institutions and corporate(s) with the objective of providing necessary linkages among different stakeholders to facilitate accelerated commercialization of biotechnology. BCIL has been actively involved in technology transfer, R& D collaborations, business support services, project consultancy, project management, biosafety & regulatory support services, IPR related services, information dissemination and manpower training related to biotechnology over the last thirty six years. BCIL is presently managing a number of prestigious projects of national relevance for various government departments including DBT, Ministry of Agriculture (MOA),Ministry of Environment & Forests and Climate Changes (MOEF & CC) and Ministry of External Affairs (MEA). BCIL is closely networking with stakeholders involved in commercialization of biotechnology i.e. Central and State Governments, scientists, research institutions, universities, entrepreneurs, corporate sector and other national and international organizations etc. BCIL has an elite Board of Directors consisting of Heads of various Govt. Departments dealing with research in biotechnology, financial institutions and industry to provide vision and guidance to BCIL in its various activities. Presently, BCIL carries its operations from its corporate and registered office at 5th Floor, Anuvrat Bhawan, 210, Deen Dayal Upadhyaya Marg, New Delhi-110002.
20	**Significant Accounting Policies**
20.1	**Basis of accounting and preparation of Financial Statements**
	The Financial Statements of the company have been prepared in accordance with the Generally Accepted Accounting Principles in India (Indian GAAP) including the Accounting Standards specified under Section 133 of the Companies Act, 2013 read with the Rule 7 of the Companies (Accounts) Rules, 2014 as amended from time to time and disclosures are made in accordance with the requirement of Schedule III of the Companies Act, 2013 as referred under section 129(1) of the Companies Act, 2013. The Financial Statements have been prepared on accrual basis under the historical cost convention .The accounting policies adopted in the preparation of the Financial Statements are consistent with those followed in the previous year.
20.2	**Use of estimates**
	The preparation of the Financial Statements in conformity with Indian GAAP requires the Management to make estimates and assumptions considered in the reported amounts of assets and liabilities (including contingent liabilities) and the reported income and expenses during the year. The Management believes that the estimates used in preparation of the Financial Statements are prudent and reasonable. Future results could differ due to these estimates and the differences between the actual results and the estimates are recognised in the periods in which the results are known / materialise.
20.3	**Depreciation and amortisation**
	i) Depreciation on fixed assets has been provided on pro-rata basis from the date of acquisition of assets on written down value method at the rates arrived at on the basis of remaining useful lfie of the assets and manner prescribed under Schedule II read with Section 123 of the Companies Act, 2013. ii) On assets sold, discarded etc, during the year, depreciation is provided upto the date of sale /discard. The value of assets whose useful life has been expired, has been adjusted with retained earnings/deferred grants. iii) Depreciation on fixed assets purchased out of capital grants is debited from Capital Reserve Account and credited to Profit and Loss Account, resulting into claiming deprecation only on the assets funded by the company.
20.4	**Revenue & Expense recognition**
	Revenue is recognized on accrual basis to the extent that it is probable that the economic benefits will flow to the Company and can be reliably measured. Accordingly, wherever there are uncertainties in the ascertainment / realization of income, the same is not accounted for. Income from Sale of Publication, Royalty (including correponding expenses) and Subscription from members is recoganised on receipt basis. Leave Travel Concession expenses is recognised on payment basis.
20.5	**Other income**
	The Dividend income from investments made in Companies and Mutual fund units is recognized as and when the Company becomes entitled to it i.e. after the declaration and approval of dividend by the Investee Company / Mutual Fund. Interest income is recognized on accrual basis taking into account, the amount invested and the rate of interest applicable on time proportionate method. Interest on tax refund, if any, is accounted for on receipt basis.

20.6	**Tangible fixed assets**
	Fixed assets have been capitalised at cost inclusive of installation expenses and are carried at cost less accumulated depreciation and impairment losses, if any. Subsequent expenditure relating to fixed assets is capitalised only if such expenditure results in an increase in the future benefits from such asset beyond its previously assessed standard of performance. Fixed assets acquired out of grants sanctioned and put to use for project purposes are capitalised and capital reserve in the nature of deferred grant is created for the equivalent amount. Depreciation on such assets is not claimed and amount equivalent to depreciation is reduced from both the fixed assets and deferred grant as well.
20.7	**Intangible assets**
	The company do not have any intangible assets for the period under review. However, intangible assets are recorded at the consideration paid for acquisition of such assets and are carried at cost less accumulated amortization and impairment.
20.8	**Foreign currency transactions and translations**
	Initial recognition
	Transactions in foreign currencies entered into by the company and its integral foreign operations are accounted at the exchange rates prevailing on the date of the transaction or at rates that closely approximate the rate at the date of the transaction.
	Measurement of foreign currency monetary items at the Balance Sheet date
	Year end balances of receivables/ payables are translated at year end rate of exchange and the resultant transaction loss/gain is recognized in the Statement of Profit and Loss.
20.9	**Government grants, subsidies and export incentives**
	Grants received & utilized from Government agencies against specific fixed assets are shown under the head "Capital Reserve"- Sub head "Deferred Grant" and depreciation on the fixed assets purchased out of grants are debited to Deferred Grant Account and credited to the Depreciation Account and depreciation in Profit and Loss Account is shown seperately. Revenue grants are shown in the profit and loss account to match the same with the related costs as per the terms of grants and unutilized grants are shown under the head "Advances Received".
20.10	**Investments**
	Investments being long term in nature are stated at cost and provision for diminution in their value other than temporary is made in the financial statements. Gains/ losses on disposal/redemption of investments are recognized as income/ expenditure, as and when realized and temporary decline in the value of investments are recognized as loss in accordance with the Accounting Standard -13 (AS-13) issued by ICAI.
20.11	**Employee benefits**
	Employee benefits include provident fund, gratuity and leave encashment.
	Defined contribution plans
	The company's contribution to provident fund are considered as defined contribution plans and are charged as an expense as they fall due based on the amount of contribution required to be made.
	Defined benefit plans
	For defined benefit plans in the form of gratuity fund and leave encashment fund, the cost of providing benefits is determined using the Projected Unit Credit method, with actuarial valuations being carried out at each Balance Sheet date. Actuarial gains and losses are recognised in the Statement of Profit and Loss in the period in which they occur. Past service cost is recognised immediately to the extent that the benefits are already vested and otherwise is amortised on a straight-line basis over the average period until the benefits become vested. The retirement benefit obligation recognised in the Balance Sheet represents the present value of the defined benefit obligation as adjusted for unrecognised past service cost, as reduced by the fair value of scheme assets. Any asset resulting from this calculation is limited to past service cost, plus the present value of available refunds and reductions in future contributions to the schemes.
20.12	**Earnings per share**
	Basic earnings per share is computed by dividing the profit / (loss) after tax (including the post tax effect of extraordinary items, if any) by the weighted average number of equity shares outstanding during the year. Diluted earnings per share is computed by dividing the profit / (loss) after tax (including the post tax effect of extraordinary items, if any) as adjusted for dividend, interest and other charges to expense or income relating to the dilutive potential equity shares, by the weighted average number of equity shares considered for deriving basic earnings per share and the weighted average number of equity shares which could have been issued on the conversion of all dilutive potential equity shares. Potential equity shares are deemed to be dilutive only if their conversion to equity shares would decrease the net profit per share from continuing ordinary operations. Potential dilutive equity shares are deemed to be converted as at the beginning of the period, unless they have been issued at a later date. The dilutive potential equity shares are adjusted for the proceeds receivable had the shares been actually issued at fair value (i.e. average market value of the outstanding shares). Dilutive potential equity shares are determined independently for each period presented. The number of equity shares and potentially dilutive equity shares are adjusted for share splits / reverse share splits and bonus shares, as appropriate.

20.13	Taxes on income
	Current tax is the amount of tax payable on the taxable income for the year as determined in accordance with the provisions of the Income Tax Act, 1961. Minimum Alternate Tax (MAT) paid in accordance with the tax laws, which gives future economic benefits in the form of adjustment to future income tax liability, is considered as an asset if there is convincing evidence that the company will pay normal income tax. Accordingly, MAT is recognised as an asset in the Balance Sheet when it is probable that future economic benefit associated with it will flow to the company. Deferred tax is recognised on timing differences, being the differences between the taxable income and the accounting income that originate in one period and are capable of reversal in one or more subsequent periods. Deferred tax is measured using the tax rates and the tax laws enacted or substantially enacted as at the reporting date. Deferred tax liabilities are recognised for all timing differences. Deferred tax assets in respect of unabsorbed depreciation and carry forward of losses are recognised only if there is virtual certainty that there will be sufficient future taxable income available to realise such assets. Deferred tax assets are recognised for timing differences of other items only to the extent that reasonable certainty exists that sufficient future taxable income will be available against which these can be realised. Deferred tax assets and liabilities are offset if such items relate to taxes on income levied by the same governing tax laws and the Company has a legally enforceable right for such set off. Deferred tax assets are reviewed at each Balance Sheet date for their realisability.
	'Current and deferred tax relating to equitt items are recognised in equity and not in the Statement of Profit and Loss.
20.14	**Provisions and contingencies**
	A provision is recognised when the company has a present obligation as a result of past events and it is probable that an outflow of resources will be required to settle the obligation in respect of which a reliable estimate can be made. Provisions (excluding retirement benefits) are not discounted to their present value and are determined based on the best estimate required to settle the obligation at the Balance Sheet date. These are reviewed at each Balance Sheet date and adjusted to reflect the current best estimates. Contingent liabilities are disclosed in the Notes.
20.15	**Service tax/GST input tax credit**
	Service tax/GST input tax credit is accounted for in the books in the period in which the Invoice of GST received and when there is no uncertainty in availing / utilising the credits.and no Input tax credit is taken on provisional basis.
20.16	**Impairment of Assets**
	The management periodically assesses, whether there is an indication that an asset may be impaired. An impairment loss is recognized wherever the carrying value of an asset exceeds its recoverable amount. The recoverable amount is higher of the assets net selling price and value in use, which means the present value of future cash flows expected to arise from the continuing use of the asset and its eventual disposal. An impairment loss, if any, is charged to the Statement of Profit and Loss in the year in which the asset is identified as impaired. The impaired loss recognized in prior accounting periods is reversed/ adjusted, if there has been a change in the estimate of the recoverable amount.
20.17	Cash Flow Statement
	Cash flows are reported using the indirect method, whereby profit before tax is adjusted for the effects of transactions of non-cash nature and any deferrals or accruals of past or future cash receipts or payments and item of income or expenses associated with investing or financing cash flows. The cash flows from operating, investing and financing activities of the company are segregated based on the available information.
20.18	**Segment Reporting**
	Business segment
	'The company identifies primary segments based on the dominant source, nature of risks and returns, the internal organisation and management structure. The operating segments are the segments for which separate financial information is available and for which operating profit/loss amounts are evaluated regularly by the executive Management in deciding how to allocate resources and in assessing performance.
	Geographical Segments
	Secondary segmental reporting is performed on the basis of the geographical location of customers i.e. within India and Outside India.
20.19	Leases
	The leases under which the company assumes substantially all the risks and rewards of ownership are classified as finance leases. Such assets acquired are capitalized at fair value of the asset or present value of the minimum lease payments at the inception of the lease, whichever is lower. Lease payments under operating leases are recognized as an expense on a straight-line basis in the Statement of Profit and Loss over the lease term.

NOTES FORMING PART OF THE FINANCIAL STATEMENTS

Note 21 Additional information to the financial statements (Rs. in lacs)

Note	Particulars		
21.1	**Contingent liabilities and commitments (to the extent not provided for)**	**As at 31 March, 2026**	**As at 31 March, 2025**
(i)	**Contingent liabilities**		
	(a) Claims against the company not acknowledged as debt	0.00	0.00
	(b) Performance Bank Guarantees	9.06	6.53
	(c) Other money for which the Company is contingently liable	16.09	16.07
(ii)	**Commitments**		
	(a) Estimated amount of contracts remaining to be executed on capital account and not provided for		
	Tangible assets	0.00	0.00
	Intangible assets	0.00	0.00
	(b) Uncalled liability on shares and other investments partly paid	0.00	0.00
	(c) Other commitments	0.00	0.00
21.2	**Disclosures required under Section 22 of the Micro, Small and Medium Enterprises Development Act, 2006**		
Note	Particulars	As at 31 March, 2026	As at 31 March, 2025
	(i) Principal amount remaining unpaid to any supplier as at the end of the accounting year	10.39	9.37
	(ii) Interest due thereon remaining unpaid to any supplier as at the end of the accounting year	0.00	0.00
	(iii) The amount of interest paid along with the amounts of the payment made to the supplier beyond the appointed day	0.00	0.00
	(iv) The amount of interest due and payable for the year	0.00	0.00
	(v) The amount of interest accrued and remaining unpaid at the end of the accounting year	0.00	0.00
	(vi) The amount of further interest due and payable even in the succeeding year, until such date when the interest dues as above are actually paid	0.00	0.00
	Dues to Micro and Small Enterprises have been determined to the extent such parties have been identified by the Management. and relied upon by the Auditors.		
21.3	**Earnings in foreign cur rency:**	**As at 31 March, 2026**	**As at 31 March, 2025**
	Export of goods calculated on FOB basis	0.00	0.00
	Royalty, know-how, professional and consultation fees	13.51	29.83
	Interest and dividend	0.00	0.00
	Other income, indicating the nature thereof.	0.00	0.00
21.4	**Expenditure in foreign exchange:**	**As at 31 March, 2026**	**As at 31 March, 2025**
	Royalty	0.00	0.00
	Know-how	0.00	0.00
	Project related expenses	12.52	21.65
	Interest	0.00	0.00
	Other matters	0.00	0.00

NOTES FORMING PART OF THE FINANCIAL STATEMENTS

21.5	**Exceptional, Extraordinary and Prior Period Items**		
	Profit on sale of Long Term Investments	0.00	0.00
	Loss on sale of Long Term Investments	0.00	0.00
	Provision for decline in value of investments written back	0.00	0.00
	Prior Period Income	0.00	0.00
	Provision for gratuity written back	10.75	6.11
	Prior Period Expenses	0.00	0.00
	Total	**10.75**	**6.11**
21.6	**Segement Reporting**		
	The company is operating into a single segment ie.to provide consultancy in biotechnology and allied areas. During the year under review, revenue of Rs. 13.51 lakhs has been generated from the segment carried out outside india and rest of the revenue relate to the indegenious operations.		
21.7	Loans & advances to Directors/KMP/Related Parties- NIL		
21.8	Details of Benami Property -NIL		
21.9	Charge/satisfaction not registered -NIL		
21.10	Title deeds of immovable property not held in the name of company -NIL		
21.11	As per the terms agreed with the MSME Creditors, no interest is payable to them. Payment to them will be made only on receipt of corresponding payments from company's clients as per the understanding with such creditors. .		
21.12	Under the new scheme of fund disbursement under Biotechnology Research and Development (150), funds from DBT shall be transferred to Central Nodal Agency (CNA) which is the National Institute of Immunology (NII, New Delhi) which in turn will assign limits to the Zero Balance Subsidiary Account (ZBSA) with ICICI Bank of all the Sub Agencies. In pursuance of the Scheme, company being a sub agency of DBT has received limits from CNA during the year which is being utilised for project activities.		
21.13	Considering the short term appointment of contractual staff, provision for gratuity has not been provided for.		

Note 22 Disclosures under Accounting Standards (Rs. in lacs)

Note	Particulars	For the year ended 31 March, 2026	For the year ended 31 March, 2025
22.1	**Details of government grants**		
22.1.a	Government grants received by the company during the year towards Subsidies, Duty drawback and other incentives	NIL	NIL
22.1.b	Equipments and facilities received free of cost/Purchase out of grant during the year from the Department of Biotechnology, Govt. of India (DBT), Ministry of Enviornment & Forests and Climate Changes , Govt. of India (MOEF & CC) and BIRAC towards implementing various projects on behalf of the DBT, MOEF & BIRAC.	0.00	0.00
22.2	**Retirement benefits**		
22.2.a	A total provision for gratuity of Rs. 140.38 lacs has been made by the company as per the valuation certificate of an independent actuarian valuer. To meet the liability towards gratuity, the company has taken coverage from the Life Insurance Corporation of India under its Group Gratuity Cash Accumulation Scheme to the extent of Rs. 157.90 lacs.		
22.2.b	A total provision for leave encashment of Rs. 133.88 lacs has been made by the company as per the valuation certificate of an independent actuarian valuer . To meet the liability towards leave encashment, the Company has taken coverage from the Life Insurance Corporation of India under its Group Leave Encashment Scheme to the extent of Rs.89.92 lacs.		

NOTES FORMING PART OF THE FINANCIAL STATEMENTS

Note 22 Disclosures under Accounting Standards (contd.)

Note	Particulars		
22.3	**Related party transactions**		
22.3a	Details of related parties:		
	Description of relationship		**Names of related parties**
	Investing company / enterprise having significant influence over the company ie. The company is an associate of IDBI Bank Limited and not vice a versa		IDBI Bank Limited
	Key Management Personnel (KMP)		Dr. Purnima Sharma Mr. Mukesh Gupta
	Note: Related parties have been identified by the Management.		

Details of related party transactions during the year ended 31 March, 2026

(Rs. in lacs)

22.3.b	Particulars	Associates	KMP	Total
		Rs.	Rs.	Rs.
	Payment for services (Salaries & perquisities) (Paid during the year	0.00 (0.00)	66.40 (69.59)	66.40 (69.59)
	Bank Deposits (Outstanding Balance)	1176.18 (1349.56)	0.00 (0.00)	1176.18 (1349.56)
	Receipt of Interest (Received during the year)	84.64 (89.79)	0.00 (0.00)	84.64 (89.79)
Note: Figures in bracket relates to the previous year				

(Rs. in lacs)

Note	Particulars	For the year ended 31 March, 2026	For the year ended 31 March, 2025
22.4	**Earnings per share**		
	Basic & Diluted		
22.4.a	Continuing operations		
	Net profit / (loss) for the year from continuing operations	12.70	5.10
	Less: Preference dividend and tax thereon	0.00	0.00
	Net profit / (loss) for the year from continuing operations attributable to the equity shareholders	12.70	5.10
	Weighted average number of equity shares	53,70,027.00	53,70,027.00
	Par value per share	10.00	10.00
	Earnings per share from continuing operations - Basic (Rs.)	0.24	0.09
22.4.b	Total operations		
	Net profit / (loss) for the year	12.70	5.10
	Less: Preference dividend and tax thereon	0.00	0.00
	Net profit / (loss) for the year attributable to the equity shareholders	12.70	5.10
	Weighted average number of equity shares	53,70,027.00	53,70,027.00
	Par value per share	10.00	10.00
	Earnings per share - Basic (Rs.)	0.24	0.09

NOTES FORMING PART OF THE FINANCIAL STATEMENTS

Note 22 Disclosures under Accounting Standards (contd.)

(Rs. in lacs)

Note	Particulars	As at 31 March, 2026	As at 31 March, 2025
22.5	**Deferred tax (liability) / asset**		
	Tax effect of items constituting deferred tax liability		
	On difference between book balance and tax balance of fixed assets	0.00	0.00
	On expenditure deferred in the books but allowable for tax purposes	0.00	0.00
	On items included in reserves and surplus pending amortisation into the Statement of Profit and Loss	0.00	0.00
	Others	0.00	0.00
	Tax effect of items constituting deferred tax liability	0.00	0.00
	Tax effect of items constituting deferred tax assets		
	Provision for compensated absences, gratuity and other employee benefits	6.65	13.06
	Provision for doubtful debts / advances	4.10	4.10
	Disallowances under Section 40(a)(i), 43B of the Income Tax Act, 1961	4.35	1.62
	On difference between book balance and tax balance of fixed assets	1.64	1.81
	Unabsorbed depreciation carried forward	0.00	0.00
	Brought forward business losses	0.00	0.00
	On items included in reserves and surplus pending amortisation into the Statement of Profit and Loss	0.00	0.00
	Others	0.00	0.00
	Net deferred tax (liability) / asset	**16.74**	**20.59**

NOTES FORMING PART OF THE FINANCIAL STATEMENTS

Note 22 Disclosures under Accounting Standards (contd.)

22.6					
Particulars	**2025-26**	**2024-25**	**Change (%)**	**Numerator**	**Denominator**
Current Ratio (in times)	2.00	1.95	2.56	Total Current Assests	Total Current Liabilities
Return on Equity Ratio (in %)	2.36	0.95	148.42	Profit / (Loss) for the year	Average Total Equity
Trade Receivable Turnover Ratio (in %)	146.75	149.00	-1.51	Revenue from Operations	Average Trade Receivable
Trade Payables Turnover Ratio (in %)	1386.09	952.79	45.48	Other Expenses	Average Trade Payables
Net Capital Turnover Ratio (in %)	149.46	25.63	483.14	Revenue from Operations	Average Working Capital
Net Proft Ratio (in %)	3.07	1.22	151.64	Profit / (Loss) for the year	Revenue from Operations
Return on Capital Employed (in %)	0.83	0.37	124.32	Profit / (Loss) for the year before tax	Average Capital Employed
Debt Equity Ratio	NA	NA	NA		
Debt Service Coverage Ratio	NA	NA	NA		
Inventory Turnover Ratio	NA	NA	NA		
Return on Investment	NA*	NA*	NA*		
*Not feasible to calculate as return on invesment of Rs. 0.19 lakhs is negligible.					
The reasons for increase/decrese in Ratios by more than 25% during the year are given below:					
(i) Return on Equity Ratio Net Profit Ratio & Return on Capital Empoyed	Increase in net profit from Rs. 5.10 lacs to Rs. 12.70 lacs				
(ii) Trade Payable Turnover Ratio	Increase in trade payables and other expenses.				
(iii) Net Capital Turnover Ration -	Decrease in Average Working Capital				

NOTES FORMING PART OF THE FINANCIAL STATEMENTS

Note 22 Disclosures under Accounting Standards (contd.)

Note	Particulars
22.7	In the opinion of the Board, the value of current assets, loans and advances have a realizable value in the ordinary course of business at least equal to that stated in the Balance Sheet.
22.8	Balances in respect of receivables, sundry debtors, project advances and creditors are subject to their confirmations. Amount receivable from Government agencies including DBT and project advances in various projects can not be confirmed due to the difference in the method of accounting deployed in these agencies and the company 's method of accounting. The balances in project advances represent unspent balance from the projects funds granted by these agencies and the same are utilized for the projects as per sanction order received from these agencies from time to time.
22.9	The company had entered into agreements with DBT (includes BIRAC) under the various schemes of DBT where by it is acting as a coordinating /managing agency. The funds received from DBT under various schemes have been kept separately in bank accounts and interest earned on these deposits is credited to the respective DBT project accounts. The interest earned is utilized only for activities to be carried on under the various schemes. However the interest earned on these funds and liability to pay such interest to the DBT has been shown net of Income & Expenditure while preparing Statement of Profit & Loss Account. These funds are specifically utilized for the schemes of DBT and only the fees received for rendering services as coordinating/ managing agency has been accounted for as income from operation in the Statement of Profit and Loss. The company is maintaining details of head wise expenditure incurred in projects coordinated by it through cost categories and cost centers.
22.10	On the presently identified facts, the potentially relevant IND AS (Indian Accounting Standards) trigger is the company status as an associate of a scheduled commercial bank namely IDBI Bank Limited who holds significant influence over the company by way of holding more than 20% share capital of the company. Ind AS could apply to the company only via the banking-sector roadmap as an associate of a scheduled commercial bank (RBI circular 11 Feb 2016); However, RBI deferred that roadmap till further notice (22 Mar 2019), still in force for FY25-26. Separately no independent listing, net-worth, subsidiary, associate, joint-venture or voluntary-adoption trigger applies. Thus, Ind AS is not applicable is not applicable to the company during the year.
Note 23 Previous year's figures	
23	Previous year's figures have been regrouped / reclassified wherever necessary to correspond with the current year's classification / disclosure.

In terms of our report attached.
For Aggarwal Vineeta & Co.
Chartered Accountants
FRN: 011645N
(Suresh Aggarwal)
Partner
M.N. 087280

UDIN -26087280NPBWNY7801

Place: New Delhi
Date: 13/07/2026

For and on behalf of the Board of Directors

(Dr. Shekhar C Mande)
Chairman
DIN-10083454

(Dr.Purnima Sharma)
Managing Director
DIN-01082972

(Mukesh Gupta)
AGM (Finance) & Company Secretary

BCIL

Biotech Consortium India Limited

CIN: U73100DL1990PLC041486

5th Floor, Anuvrat Bhawan, 210, Deen Dayal Upadhyay Marg,

New Delhi-110 002Phones:

+91 (011) 23219064-67, Fax: +91 (011) 23219063,

E-mail: info.bcil@biotech.co.in

Website: www.biotech.co.in